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ABSTRACT
Adenylyl cyclase (AC) catalyzes the formation of the ubiquitous second
messenger cAMP. AC isoforms differ in their tissue distribution, cellular localization,
regulation, and protein interactions, and most cells express multiple isoforms. We
hypothesized that cAMP produced by different AC isoforms regulates unique cellular
responses. Overexpression of individual isoforms had distinct effects on forskolin (Fsk)induced expression of a number of known cAMP-responsive genes in human bronchial
smooth muscle cells (BSMC) and human embryonic kidney cells (HEK-293). Most
notable, in BSMC overexpression and activation of AC2 enhanced interleukin 6 (IL-6)
expression, but overexpression of AC3 or AC6 had no effect. IL-6 production by BSMC
was induced by Fsk and select G protein-coupled receptor (GPCR) agonists, though IL-6
levels did not directly correlate with intracellular cAMP levels. At low cAMP
concentrations exchange protein directly activated by cAMP (Epac) predominated in
mediating the IL-6 response, but at higher cAMP concentrations protein kinase A (PKA)
assumed the larger role. IL-6 promoter mutations demonstrated that activator protein 1
(AP-1) and cAMP responsive element (CRE) transcription sites were required for cAMP
mediated induction. Our findings indicate that AC2 participates in a cAMP-signaling
compartment that specifically regulates IL-6 expression in BSMC and that other AC
isoforms are excluded from this compartment.
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CHAPTER 1.

INTRODUCTION

G protein-coupled receptors (GPCR) are one of the most utilized targets for
therapeutic drugs, with up to 50% of pharmaceuticals acting at these receptors (Salon et
al. 2011). Stimulation of a receptor results in generation of second messengers such as
cyclic adenosine monophosphate (cAMP), inositol trisphosphate (IP3), and
diacylglycerol, and then signal transduction proceeds through a wide range of
downstream effectors. GPCR regulate numerous physiological responses depending on
the ligand, receptor, and cell-type. With few second messengers initiating a huge array of
potential responses, cells must have mechanisms in place to direct the proper response
upon agonist binding, however the mechanisms responsible are poorly understood. We
are interested in how cells integrate and separate common signaling pathways and
produce distinct responses. We hypothesize that signaling compartments are essential for
directing specific cellular responses from a given GPCR. A better understanding of
intracellular signaling compartments could allow for more specifically targeted
therapeutics.
Bronchial Smooth Muscle and Asthma
Bronchial smooth muscle cells (BSMC) are critical in the pathogenesis and
treatment of asthma. They possess secretory and contractile properties and are involved
in the airway hyper-responsiveness, constriction, and remodeling that occur in asthma
(Tliba and Panettieri 2009). In asthmatics there is an increase in both the size and
number of airway smooth muscle cells (James et al. 2012). Asthmatic BSMC produce
and secrete higher levels of inflammatory cytokines and extra cellular matrix proteins,
contributing to inflammation and remodeling (Oliver et al. 2006; Johnson et al. 2004). It
has been debated whether the pro-inflammatory environment of the asthmatic airway or
changes to the cells themselves are responsible for alterations in the structure and
function of airway smooth muscle (ASM) in asthma, and there is evidence that both play
a role (Shore 2004). Bronchoalveolar lavage fluid (BALF) from allergen-challenged
asthmatics causes increased proliferation of normal BSMC in culture, suggesting that the
environment could be responsible for some of the phenotypic changes observed in asthma
(Naureckas et al. 1999). A number of studies have also shown intrinsic differences in
BSMC from asthmatic and nonasthmatic airways (Yeganeh et al. 2013). In vitro BSMC
from asthmatic donors show greater contractility in response to histamine (Matsumoto et
al. 2007). Genetic changes have also been observed that might explain phenotypic
differences in BSMC of asthmatics (Oliver et al. 2006; Martin and Jo 2008; Roth et al.
2004).
GPCR signaling pathways, key to the pathogenesis and treatment of asthma, are
also altered in BSMC of asthmatics. An imbalance of pro-contractile to pro-relaxant
signaling occurs in asthma (Billington and Penn 2003). β-adrenergic receptor (βAR)
agonists are less potent inducers of relaxation in carbachol contracted bronchial strips
from asthmatic donors, suggesting reduced number or activity of the receptors (Goldie et
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al. 1986). Polymorphisms in β2AR have been shown to enhance receptor downregulation and may increase the propensity to develop certain types of asthma (Small et
al. 2003; Turki et al. 1995). In addition to changes at the level of the receptor,
phosphodiesterase (PDE) 4 expression and activity is increased in asthmatic BSMC, thus
reducing cAMP signaling and further shifting the balance toward contraction (Trian et al.
2011). The shift in the balance of contractile to relaxant signaling may contribute to
development and severity of asthma.
Airway constriction associated with asthma is treated with βAR agonists, which
stimulate smooth muscle relaxation and bronchodilation largely through cAMP signaling
pathways. Intermittent asthma can be treated at the time of exacerbation with short-acting
βAR agonists for rapid bronchodilation. In moderate or severe asthma, in addition to
short-acting βAR agonists as needed, long-acting βAR agonists are used in combination
with inhaled corticosteroids as maintenance therapy (National Asthma and Prevention
2002). βAR agonists cause relaxation by activating cAMP signaling pathways and
potassium channel activity, but they can also initiate several other responses, and some
are detrimental to the asthmatic airway as discussed below.
GPCR and cAMP Signaling
GPCR are membrane-spanning proteins with extracellular ligand binding pockets
and intracellular coupling to G-proteins. When a hormone, neurotransmitter, or drug
binds to a GPCR on the cell surface, it initiates an intracellular signaling cascade. Ligand
binding to the GPCR results in a conformational change of the receptor and interactions
with G-proteins leading to GTP exchange and dissociation of the heterotrimeric G protein
into Gα and Gβγ subunits. G-proteins have particular effects depending on their subtype.
Gαs stimulates and Gαi inhibits activity of adenylyl cyclase (AC), the enzyme that
catalyzes the formation of cAMP from adensine triphosphate (ATP). Gαq activates
phospholipase C (PLC) that initiates pathways involved in phospholipid and Ca2+
signaling though IP3 and diacylglycerol (Pierce et al. 2002). Each cell can express many
GPCR, allowing it to respond to a variety of stimuli (Insel et al. 2012). In BSMC, GPCR
signaling regulates cell cycle progression, contraction (Gαq, Gαi) and relaxation (Gαs), and
gene expression, among many other processes (Billington and Penn 2003).
Following Gαs stimulation, AC catalyze the formation of cAMP from ATP.
cAMP regulates many cellular processes by activating protein kinase A (PKA) and
exchange protein directly activated by cAMP (Epac) (Walsh et al. 1968; de Rooij et al.
1998). cAMP signaling is important in the treatment of asthma, because it causes
relaxation of BSMC and dilation of the airway. Upon activation by cAMP, PKA
phosphorylates several targets that lead to relaxation of smooth muscle cells (Knox and
Tattersfield 1995). Calcium is the primary mediator of contraction, and cAMP signaling
pathways oppose contractile pathways by regulating intracellular calcium concentrations
and calcium sensitivity of contractile machinery. cAMP inhibits IP3-mediated Ca2+
release and facilitates Ca2+ uptake by the sarcoplasmic reticulum (Murthy 2001). PKA-
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mediated phosphorylation of phospholamban reduces intracellular calcium by relieving
phospholamban’s inhibition of sarcoplasmic reticulum calcium pump ATPase channels
(Prakash et al. 1997; Simmerman et al. 1986). Smooth muscle contraction occurs via
myosin cross bridge cycling, and PKA plays a role in regulating the process.
Phosphorylation of myosin light chain increases interactions with actin and ATPase
activity and results in contraction. PKA phosphorylation promotes relaxation by
decreasing the activity of myosin light chain kinase and increasing activity of myosin
light chain phosphatase (Conti and Adelstein 1981; Pfitzer 2001; Wooldridge et al. 2004).
Gαs and PKA also facilitate βAR-mediated relaxation by activating potassium channels
(Kume et al. 1994). The pro-relaxant actions of cAMP are taken advantage of in the
treatment of asthma by βAR agonist therapies.
βAR Agonists
βAR agonists activate the cAMP signaling pathways described above and are
used for bronchoprotection and as rescue treatment in asthma. The goal of βAR agonist
therapy is to cause relaxation of smooth muscle and bronchodilation through Gαs and
cAMP signaling, but βAR agonists can also induce other signaling pathways that are not
favorable in the asthmatic airway. Two main downsides of βAR agonists are changes in
βAR coupling and desensitization. β2AR that initially couple to Gαs can undergo Gswitching upon exposure to agonist (Daaka et al. 1997b). Switching to Gαi coupling leads
to activation of mitogen activated protein kinase (MAPK) cascades that induce
expression of pro-inflammatory genes and can worsen asthma (Pelaia et al. 2005). β2AR
can also exhibit atypical coupling to Gαq, which increases Ca2+ and contractile responses
(Anderson 2006). Chronic βAR agonist exposure leads to tolerance and desensitization
(Cooper et al. 2011; Benovic et al. 1985). Several mechanisms can play a role in
desensitization and downregulation of βAR following stimulation, which result in
decreased responsiveness to therapy over time (Lohse et al. 1990; Giembycz and Newton
2006). Phosphorylation by PKA reduces receptor affinity for Gαs and increases affinity
for Gαi (G switching) (Daaka et al. 1997a). Phosphorylation by G protein coupledreceptor kinase (GRK) recruits β arrestin and facilitates internalization of the receptor via
clathrin-coated pits (Benovic et al. 1988). Due to altered coupling and responsiveness of
βAR, treatment with βAR agonists alone can lead to increased hyperresponsiveness and
inflammation, reduced bronchodilation, and even increased risk of morbidity and
mortality (Cheung et al. 1992; Johnston and Edwards 2009; Strandberg et al. 2007). In
the future AC may represent a better therapeutic target with fewer unintended effects,
since only cAMP pathways would be activated without Gαi or Gαq activation.
Approaches targeting AC also have the potential to create larger changes in cAMP, since
AC is the limiting component in βAR-stimulated cAMP production(Ostrom et al. 2000b).
cAMP Signaling Compartments
cAMP is ubiquitous and mediates many responses in BSMC. It would not be
practical for cAMP to freely float around the cell activating numerous pathways in
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response to each stimulus, and in fact steady state concentrations would likely not be high
enough to activate PKA (Rich et al. 2000). Compartmentalized cAMP signaling allows
specific responses to stimuli. The first examples of compartmentation of cAMP signals
were described in myocardium where it was observed that of two agonists, epinephrine
and prostaglandin E1 (PGE1) that act through cAMP and PKA, only epinephrine
stimulated contractile force and glycogen phosphorylase activity (Keely 1977, 1979).
Homogenate fractionation showed that these stimuli activated PKA in different
compartments (Buxton and Brunton 1983). Compartmentation involves components both
upstream and downstream of cAMP production. There are nine AC isoforms, which
differ in their tissue distribution, regulation (Table 1-1), cellular localization, and
associations with other proteins. We hypothesize that the differences among isoforms
help them define unique cAMP compartments and lead to AC isoform-specific cellular
and physiological responses.
Several components in addition to AC contribute to establishment of cAMP
signaling compartments. PDE hydrolyze cAMP, limiting its diffusion from the site of
production (Mika et al. 2012). A-kinase anchoring protein (AKAP) scaffolding molecules
bring together multiple signaling molecules in complexes (Smith et al. 2006). Over 50
AKAP have been described, and like AC they have unique tissue distribution,
intracellular localization, and interactions (Dessauer 2009). In addition to prearranging
signal cascades, AKAP bind PDE and regulators of AC, keeping cAMP near the site of
production. AKAP and direct complexes containing AC allow for rapid and precise
signaling to generate specific cellular responses downstream of a given stimulus (Ostrom
et al. 2012).
Although specific physiological responses following activation of different Gαs
receptors have been known since the 1970’s, AC isoform-specific responses have only
recently been described. AC5 and AC6, though similar in their structure and regulation,
have been shown to have unique roles in the heart through overexpression and knockout
studies (Pierre et al. 2009). In cardiomyopathy models, AC6 overexpression increases
survival and heart function (Roth et al. 2002). Conversely, it is knockdown of AC5 that
is cardioprotective (Vatner et al. 2009). Differences in the localization and associations
of AC5 and AC6 appear to drive the isoform-specific effects in cardiomyocytes. AC6 is
located outside T-tubules where it colocalizes with β2AR (Timofeyev et al. 2013). AC6
activation in response to βAR agonist results in increased L-type calcium current
(Timofeyev et al. 2013). AC5 on the other hand is localized to T-tubules where it is in a
complex containing PDE, and cAMP diffusion is tightly constrained and unable to alter
calcium currents (Timofeyev et al. 2013). Interestingly, even a catalytically inactive AC6
mutant has been shown to have beneficial effects when overexpressed in mice with
cardiomyopathy, likely by regulating Akt signaling through direct interactions with PH
domain and Leucine rich repeat Protein Phosphatase 2 (Gao et al. 2009; Gao et al. 2011).
The benefits of AC6 signaling in failing hearts are so promising that clinical trials are
underway utilizing AC6 gene transfer in patients with congestive heart failure (Tang et al.
2012). Other examples of AC isoform-specific regulation of cellular responses have been
described in vascular and airway smooth muscle. In vascular smooth muscle, AC1
mediates proliferation, while AC6 has no impact on proliferation but is involved in
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Table 1-1.

Isoform-specific regulation of adenylyl cyclases

Regulator

Effect

G protein
Gs
Gi

Stimulation All Isoforms
Inhibition
AC1, AC5, AC6; not AC2

Gβγ

AC subtype

References
(Iyengar 1993)
(Taussig et al. 1993a) (Federman et al. 1992) (Chen and
Iyengar 1993) (Taussig et al. 1994)
(Taussig et al. 1993b) (Bayewitch et al. 1998)
(Tang and Gilman 1991) (Gao and Gilman 1991)
(Gao et al. 2007)

Inhibition
AC1, AC5, AC6
Stimulation AC2, AC4
Conditional AC5, AC6

Forskolin

Stimulation All Isoforms (including AC9)

(Onda et al. 2001) (Premont et al. 1996) (Cumbay and Watts
2004)

Calcium/Calmodulin
Ca2+/CaM
Ca2+

Stimulation AC1, AC3, AC8
Inhibition
AC5, AC6

(Tang et al. 1991) (Choi et al. 1992) (Cali et al. 1994)
(Yoshimura and Cooper 1992) (Katsushika et al. 1992)

Kinase Regulation
PKC

Stimulation AC1, AC2, AC3, AC5, AC7

(Jacobowitz et al. 1993) (Jacobowitz and Iyengar 1994) (Bol
et al. 1997) (Kawabe et al. 1994) (Watson et al. 1994)
(Lai et al. 1997)
(Iwami et al. 1995) (Chen et al. 1997)
(Wayman et al. 1996) (Wei et al. 1996)
(Ding et al. 2004)

PKA
CaM Kinase
Raf kinase

Inhibition
Inhibition
Inhibition
Stimulation

AC6
AC5, AC6
AC1, AC3
AC2, AC5, AC6

Reprinted with permission.       $(&'(%   
    !     )-*$'% *"'(!
 '&!'&&,#&&('&"&''"&+.+
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With knowledge of differences among AC isoforms and compartmentalization of
cAMP signaling, we hypothesized that BSMC possess AC isoform-specific regulation of
cellular processes. We examined regulation of cAMP-responsive genes in BSMC
overexpressing individual AC isoforms and uncovered a number of genes that are
regulated in an isoform-specific manner. AC2-derived cAMP selectively regulates
expression of the pro-inflammatory cytokine interleukin 6 (IL-6), a key contributor to the
pathogenesis of asthma. cAMP induces IL-6 production, but the levels of cAMP and
IL-6 are not directly correlated. AC2’s unique localization, regulation and interactions
allow it to activate PKA and Epac in a signaling compartment associated with induction
of IL-6. AC6-derived cAMP is tied to regulation of other genes, but PDE limit this
cAMP pool from activating components involved in IL-6 induction. The cAMP
compartments and signaling pathways responsible for stimulation of IL-6 transcription
appear to be altered in asthma. βAR agonists currently represent the best therapy for
treatment of bronchoconstriction in asthma, but some of the signaling pathways activated
by βAR worsen inflammation and constriction. Targeting AC directly instead of through
βAR and Gαs would stimulate cAMP production without activation of Gαi and Gαq and
could result in greater cAMP production. We show that cAMP can also mediate
undesirable responses in BSMC, in particular induction of IL-6. Since cAMP signaling is
highly compartmentalized, therapeutics targeting AC6 may stimulate ASM relaxation and
bronchodilation without inducing IL-6 production. A greater knowledge of cAMP
signaling compartments could allow highly targeted treatment for many diseases,
including asthma.
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CHAPTER 2.

METHODS

Materials
Forskolin (Fsk), isoproterenol (Iso), 3-isobutyl-1-methylxanthine (IBMX),
Adenosine 5′-[γ-thio]triphosphate (ATPɣS), Arginine vasopressin (AVP), prostaglandin
D2 (PGD2), glucagon, 5′-(N-Ethylcarboxamido)adenosine (NECA), calcitonin gene
related peptide (CGRP), and substance P were purchased from Sigma; 8-Br-cAMP,
8CPT-2Me-cAMP, GF 109203X, SB 202190, (±)-SKF-83566, SQ22,536 and
wortmannin from Tocris, and butaprost (buta) from Cayman.
Wild-type and mutant IL-6 promoter luciferase constructs were purchased from
the Belgian Coordinated Collections of Micro-organisms/LMBP; LMBP acquisition
numbers 4495, 4496, 4498, 4499, 4500 (Vanden Berghe et al. 1998; Plaisance et al.
1997). Luciferase constructs contain 1168 bp of the human IL-6 promoter (wild-type or
with point mutations in specific promoter elements) upstream of LUCm in pGL3-Basic
vector. Binding sites were altered by site-directed mutagenesis to prevent transcription
factor binding at the following promoter elements: 3’ or 5’ activator protein 1 (AP-1) site,
cAMP response element (CRE), CCAAT-enhancer-binding proteins (C/EBP), or nuclear
factor kappa-light-chain-enhancer of activated B cells (NFκB) sites.
Cell Culture
Human BSMC purchased from Lonza were grown in smooth muscle basal
medium supplemented with the SmGM-2 bullet kit (5% fetal bovine serum, 0.1% insulin,
0.1% human epidermal growth factor, 0.2% human fibroblast growth factor-β ,and
gentamicin sulfate/amphotericin B; Lonza). Cells were kept at 5% CO2 and 37° C.
Experiments were performed on cells from passage 5-13.
Human embryonic kidney 293A cell line (HEK-293) purchased from Invitrogen
were grown in Dulbecco's Modified Eagle's medium (DMEM) (high glucose) with 10%
fetal bovine serum, 0.1 mM MEM Non-Essential Amino Acids, 2 mM L-glutamine, and
1% Pen-Strep. Cells were kept at 5% CO2 and 37° C.
AC Overexpression
Adenoviral constructs expressing rat AC2, rat AC3, mouse AC6, or lacZ (control)
cDNA were used for AC overexpression studies in BSMC. The titer of AC virus was
chosen to give similar global cAMP levels in response to 1 µM Fsk. Cells were infected
18-24 h before treatment.
Plasmids encoding rat AC2, human AC6, or the empty pEGFP-n1 vector were
used for overexpression studies in HEK-293. Cells were transfected with Cal-Phos
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calcium phosphate transfection kits (Clontech) 24 h after plating. Cells were transfected
with 3 µg plasmid per 60 mm dish. For polymerase chain recaction (PCR) arrays Fsk
was added 24 h after transfection and RNA was isolated 24 h later as described for PCR
array below.
PCR Array
Following treatment cells were lysed and RNA was isolated using RNeasy kit
with on-column DNase step (Qiagen). RNA purity and yield were determined with
Nanodrop spectrophotometer. 1 µg RNA was reverse transcribed using RT2 first strand
kit (SABioscience). cDNA from a single sample was combined with RT2 SYBR Green
Master Mix (SABioscience) and distributed among wells of a multiwell plate containing
gene specific and control primers on Human cAMP/Ca2+ PathwayFinder RT² Profiler™
or Human G Protein Coupled Receptors 384HT RT² Profiler™ PCR Array
(SABioscience). The crossing point (CP) was determined by the second derivative
maximum algorithm on Roche Lightcycler 480, and fold change was calculated by ΔΔCP
method. Melt curve analysis was used to exclude any gene whose CP may have been
artificially reduced by multiple amplification products.
qRT-PCR
For quantitative reverse transcriptase PCR (qRT-PCR) RNA was isolated as
described for PCR arrays. 1 µg RNA was reverse transcribed using Transcriptor First
Strand cDNA Synthesis Kit (Roche) and oligo (dT)18 primer. PCR was carried out on
Roche Lightcycler 480: 10 min 95° C followed by 45 cycles of 95° C for 10 s, 55° C for
30 s, 72° C for 6 s. Amplification was detected by SYBR green (KAPA) and single PCR
products were confirmed by melt curve analysis. Fold regulation was calculated by
ΔΔCP method with normalization to RPL13A housekeeping gene. The following genespecific primer sets were used:
IL-6 Forward: GAC AGC CACTCA CCT CTT CA
IL-6 Reverse: AGT GCCTCT TTG CTG CTT TC
SST Forward: TCT GAA CCC AAC CAG AAG GAG AAT
SST Reverse: GCT CAA GCC TCA TTT CAT CCT GCT
ELISA
IL-6 in cell culture medium was measured by sandwich ELISA according to
manufacture’s instructions (IL-6: eBioscience or BD bioscience, SST: Phoenix). ELISA
were read on Synergy HT (Biotek) plate reader.
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IL-6 Promoter Activity Assay
BSMC were plated 30,000 cells per well in 12-well plates. 18-24 h after plating,
each well was transfected with 1.8 µg plasmid expressing the human IL-6 promoter
driving firefly luciferase expression. Cells were co-transfected with 0.4 µg Renilla
luciferase intended as an internal control constitutively expressed via the thymidine
kinase promoter. However, Fsk treatment affected Renilla luciferase expression, so it
could not be used for normalization in our studies. All transfections used the CalPhos
(Clontech) calcium phosphate kit. Experiments were begun 48 h post-transfection.
Following treatment with the indicated drugs for 6 h, cells were scraped in 250 µL
passive lysis buffer and assayed using the Dual Luciferase Reporter Assay System
(Promega). Luminescence was measured with a TD-20/20 luminometer (Turner
Designs).
cAMP Assay
Cells were washed three times with serum- and NaHCO3-free Dulbecco's
Modified Eagle's medium (DMEM) supplemented with 20 mM HEPES, pH 7.4
(DMEH). After equilibration at 37 ̊C for 30 min, cells were pretreated with 0.2 mM
IBMX, a broadly specific PDE inhibitor, then exposed to the indicated drug for 10 min.
Assay medium was aspirated and 150 μL 5% trichloroacetic acid was added to each well
to terminate the reaction. cAMP content of the lysis buffer extract was quantified using
the cAMP EIA Kit (Cayman Chemical) using the manufacturer’s acetylation protocol.
Data Analysis and Statistics
Data are presented as the mean ± SEM. Statistical comparisons (t tests and oneway analysis of variance) were performed and graphics were generated using GraphPad
Prism 5.0f (GraphPad Software Inc., San Diego, CA).
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CHAPTER 3.

cAMP-MEDIATED GENE REGULATION IS AC
ISOFORM-DEPENDENT
Introduction

BSMC predominantly express AC isoforms 2, 4 and 6 (Bogard et al. 2011). These
isoforms differ in their regulation (Table 1-1), localization, and interactions with other
proteins, giving them the potential to signal in unique ways and control distinct responses
even when expressed in the same cell. AC isoforms are divided into 4 groups based on
their structure and features of their regulation. Group I consists of AC1, AC3, and AC8;
group II: AC2, AC4, and AC7; group III: AC5 and AC6; and group IV: AC9 (Patel et al.
2001). In BSMC, AC6 is localized to lipid rafts where it colocalizes with β2AR (Bogard
et al. 2011). AC2 and AC4 are excluded from lipid rafts and colocalize with
prostaglandin E2 receptors (EP2R) (Bogard et al. 2011). BSMC express several AKAP
scaffolding molecules, which arrange signaling complexes and interact with AC in an
isoform-specific manner (Dessauer 2009; Horvat et al. 2012). AC2 is known to interact
with multiple AKAP including mAKAP, Yotiao/AKAP9, and AKAP79/150, which bring
cAMP produced by AC2 in close proximity to prearranged signaling cascades and
regulators such as PDE and phosphatases (Piggott et al. 2008; Kapiloff et al. 2009; Scott
et al. 2013). AC6 is also associated with AKAP, and it has been shown to interact
directly with AKAP79 (Efendiev et al. 2010).
AC is the limiting factor in determining the maximal effect following Gαs-coupled
receptor stimulation (Ostrom et al. 2000b; Gao et al. 1998). Overexpression of AC
enhances responses to Gαs-coupled receptor stimulation. In BSMC we use adenoviral
overexpression of AC and subtractive analysis to study responses mediated by individual
isoforms. BSMC have low transfection efficiency, but adenoviral infection results in a
high percentage of cells overexpressing protein of interest. β galactosidase assays
confirmed over 90% of BSMC are positive for lacZ when infected with lacZ encoding
adenovirus (Bogard et al. 2011). Knockdown of AC isoforms with siRNA would be an
alternative approach and is appealing, since the individual isoforms that are left would be
expressed at endogenous levels. However, a high degree of knockdown would be
unlikely due to the long half-life of AC, and it would be particularly difficult in poorly
transfected cells such as BSMC. We also used newly characterized AC inhibitors
selective for particular AC isoforms. A number of pharmacological inhibitors have been
used to study AC isoforms, but questions were raised about claims of presumed isoform
selectivity of these inhibitors. Two recent studies sought to better describe the effect of
inhibitors on particular AC isoforms. Though previously described as an AC5-selective
inhibitor, SQ22,536 inhibits AC5 and AC6 equally. The IC50 for SQ22,536 at AC6 is
5.8 µM, and its IC50 at AC2 is 210 µM (Brand et al. 2013). Conley et. al. screened over
700 compounds and identified SKF-83566 as an AC2-selective inhibitor (2013). We
hypothesized that differences among AC isoforms and compartmentation of cAMP
signaling allows AC isoform-specific regulation of gene expression. We used PCR
arrays and isoform-specific AC inhibitors to show that some cAMP-responsive genes are
differentially regulated by individual AC isoforms in BSMC.
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Results
A number of genes are differentially regulated by overexpression and activation of
specific AC isoforms
We tested the hypothesis that cAMP produced by a particular AC isoform has
unique effects on gene expression by using PCR arrays to examine 84 cAMP- and Ca2+sensitive genes. PCR arrays allow simultaneous analysis of multiple genes by utilizing
specially designed primer pairs such that all have been optimized for amplification of
their specific target under identical conditions. Control or AC overexpressing cells were
treated with 1 µM Fsk for 24 h before RNA was isolated and reverse transcribed. The
resulting cDNA was diluted in SYBR green master mix and distributed among the wells
of the PCR array, each with a primer pair specific to a particular gene or control.
Expression of each gene in AC overexpressing cells treated with Fsk was
compared to Fsk-treated control cells. Control cells were transfected with empty
pEGFP-n1 vector or treated with an adenovirus expressing the lacZ gene. Fold change
was calculated by the ΔΔCP method with respect to lacZ Fsk-treated cells. A change in
expression of 3-fold or greater was the cutoff we used to highlight genes that were
upregulated or downregulated upon AC overexpression. For genes that displayed a
substantial change with AC overexpression, we examined whether there were differences
in gene regulation based on overexpression of individual isoforms. Changes in RNA
levels smaller than 3-fold might be physiologically significant, but we choose to focus on
the larger responses in this study. Although Fsk treatment altered the expression of many
of the genes compared to vehicle in control BSMC, we focused on genes that were
differentially regulated with overexpression of specific AC isoforms.
BSMC
Adenoviral vectors were used to overexpress AC2, AC3, AC6, or lacZ (control)
in BSMC. AC2 and AC6 are natively expressed in distinct membrane microdomains in
BSMC and AC3 was included as a representative group I isoform. AC overexpression
altered the Fsk-induced expression of 13 of the cAMP-sensitive genes tested by at least
3-fold in BSMC (Table A-1). The genes of greatest interest were those that were
differentially regulated when different AC were overexpressed. Overexpression of AC3
did not produce a 3-fold or greater change in any of the genes tested; however, AC2 and
AC6 had distinct effects on expression of a number of genes (Figure 3-1). AC2 and AC6
overexpression could enhance or attenuate Fsk induction and had differing effects
depending on the AC isoform and the gene. A subset of genes was chosen to
demonstrate the diversity of responses with different AC isoforms overexpressed, and
results are graphed as fold change with respect to lacZ to illustrate the effect of the
individual AC being overexpressed (Figure 3-1). Fsk-mediated expression of
amphiregulin (AREG) was augmented to a greater extent by AC6 overexpression than
AC2. AC2 overexpression reduced the expression of secretogranin II (SCG2), while
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Figure 3-1. Fsk-induced gene regulation in AC overexpressing BSMC compared
to control BSMC
RT2 q PCR arrays (SA Biosciences) were used to measure mRNA levels following 24 h
treatment with 1μM Fsk. mRNA levels of AC overexpressing, Fsk-treated cells are
expressed as fold change with respect to lacZ (control), Fsk- treated cells. Amphiregulin
(AREG), Secretogranin II (SCG2), Cyclin D1 (CCND1), Interleukin 6 (IL-6),
Somatostatin (SST). Dashed line represents no change with respect to lacZ. Data are
presented as fold change with respect to lacZ, mean ± SEM, n=3.
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AC6 overexpression reduced the expression of cyclin D1 (CCND1). Fsk-mediated
expression of Interleukin 6 (IL-6) was enhanced only by AC2 overexpression and
somatostatin (SST) was enhanced only by AC6 overexpression (Figure 3-1). IL-6 and
SST were targets for further study due to their clear AC isoform-dependent patterns of
gene regulation in BSMC.
HEK-293
After finding that gene expression can be regulated differently by AC isoforms in
BSMC, HEK-293 cells were tested to determine whether this is a generalizable
phenomenon or unique to BSMC. HEK-293 cells were transfected with AC2, AC6, or
pEGFP-n1 (control) vectors then exposed to 1 µM Fsk for 24 h. As in BSMC, expression
of some cAMP-sensitive genes was altered by AC overexpression. Different genes were
impacted by AC overexpression in the different cell types, and in HEK-293 the effects of
AC overexpression tended to be smaller (Figure 3-2 and Table A-2). As in BSMC, AC
overexpression could enhance or reduce Fsk-induced RNA expression in HEK-293 in an
isoform-specific manner. Calponin 1 (CNN1) RNA levels were reduced by AC6
overexpression, but not AC2. Gastric inhibitory polypeptide receptor (GIPR) expression
was enhanced only by AC2 overexpression and tumor necrosis factor (TNF) expression
was enhanced only by AC6 overexpression (Figure 3-2).
Fsk-induced SST mRNA expression and protein production is specifically regulated
by AC6 in BSMC
In the PCR array, overexpression of AC6 enhanced Fsk-induced SST mRNA
expression by 9.73 fold in BSMC, while AC2 overexpression had no effect on SST
expression (Figure 3-1). 24 h was a reasonable starting point for measuring Fskstimulated expression of many different genes in the array, but once SST and IL-6
emerged as genes of interest with specific regulation by different AC isoforms, time
course studies were completed to determine the optimal treatment time for further
experiments. SST mRNA peaked at 3 h in response to 1 µM Fsk (Figure 3-3).
One µM Fsk resulted in a particularly robust induction of the SST gene, so
0.3 µM Fsk treatments were used in subsequent studies to avoid a saturation of the
response that might prevent noticeable enhancement by AC overexpression. Exposure to
0.3 µM Fsk for 3 h caused a 26.68-fold increase in SST mRNA compared to vehicle in
control cells (Figure 3-4). With overexpression of AC6, the effect of Fsk was enhanced
and SST mRNA was 67.48-fold above vehicle. AC2 overexpression did not alter SST
when compared to control cells with native AC expression (25.74-fold over vehicle).
To determine if the increased SST mRNA in AC6 overexpressing cells results in
increased protein, we used ELISA to measure SST in cell culture medium. As early as
3 h the effect of AC6 overexpression was observed as increased SST protein
(Figure 3-5). AC6 overexpression more than doubled Fsk-induced SST production by
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Figure 3-2. Fsk-induced gene regulation in AC overexpressing HEK-293
compared to control HEK-293
RT2 q PCR arrays (SA Biosciences) were used to measure mRNA levels following 24 h
treatment with 1μM Fsk. mRNA levels of AC overexpressing, Fsk-treated cells are
expressed as fold change with respect to empty pEGFP-n1 vector (control), Fsk- treated.
Calponin 1 (CNN1), Gastric inhibitory polypeptide receptor (GIPR), Tumor necrosis
factor (TNF). Dashed line represents no change with respect to empty vector. Data are
presented as fold change with respect to empty vector, n=1.
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Figure 3-3. Time course of Fsk-induced SST mRNA expression
SST mRNA expression was measured by qRT-PCR in AC6 overexpressing cells exposed
to 1 µM Fsk for the indicated time. SST mRNA levels are expressed with respect to lacZ
basal, n=1.
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Figure 3-4. Fsk-induced SST mRNA expression in AC overexpressing BSMC
qRT-PCR was used to determine SST RNA expression in BSMC treated with 0.3 µM Fsk
for 3 h. Data are presented as fold change with respect to lacZ basal, mean ± SEM, n=3.
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Figure 3-5. Fsk-induced SST protein production in AC overexpressing BSMC
ELISA were used to measure SST secreted into culture medium by BSMC treated with
0.3 µM Fsk for 3 h. Data are presented as pg/mL SST. n=1-2.
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BSMC in 3 h, from 50.29 pg/mL to 111.69 pg/mL. AC2 overexpression did not enhance
SST production (Figure 3-5).
Fsk-induced IL-6 mRNA expression and protein production is specifically regulated
by AC2 in BSMC
AC2 overexpression clearly enhanced Fsk induction of IL-6 in the PCR array, but
AC6 overexpression had no effect. In control BSMC, time course studies showed that
IL-6 mRNA peaked at 1 h in response to 1 µM Fsk (Figure 3-6). At 1 h, 1 µM Fsk
increased IL-6 mRNA in control cells by 8.16-fold (Figure 3-7A). The enhancement of
IL-6 mRNA levels by AC2 overexpression was less pronounced at 1 h (Figure 3-7A)
than 24 h (Figure 3-1), but since Fsk-stimulated IL-6 mRNA levels peaked at 1 h, this
time point was used in all subsequent studies. AC2 overexpression resulted in a near
doubling of IL-6 mRNA compared to control cells also exposed to 1 µM Fsk for 1 h.
AC6 did not alter Fsk-induced IL-6 expression compared to control cells (Figure 3-7A).
To determine if the increased IL-6 mRNA in AC2 overexpressing cells translated
to increased protein, IL-6 protein secreted into culture medium was measured by ELISA.
1 µM Fsk resulted in IL-6 protein production that increased sharply between 10 and 24 h
then continued to accumulate over time (Figure 3-8). 24 h was chosen as the time point
for all other studies measuring IL-6 protein. Unlike mRNA, where Fsk induced a
8.16-fold increase over vehicle in control cells, IL-6 protein levels were only slightly
increased by Fsk (Figure 3-7B). In control cells 24 h Fsk treatment increased IL-6 by
11% (from 594 pg/mL in vehicle-treated cells to 668 pg/mL in Fsk-treated). AC2
overexpression enhanced Fsk-induced IL-6 protein production to 942 pg/mL.
Overexpression of AC6 did not increase IL-6 over control cells, and in fact IL-6 was
slightly lower in AC6 overexpressing cells (652 pg/mL) compared to control BSMC with
native AC expression (Figure 3-7B).
Recent studies characterizing AC inhibitors have identified SKF-83566 as AC2selective and SQ22,536 as AC5/6-selective (Conley et al. 2013; Brand et al. 2013). We
used these inhibitors as another approach to investigate the AC2-specific induction of
IL-6. We pretreated BSMC with each of these inhibitors prior to 1 µM Fsk treatment.
Pretreatment with 30 µM SKF-83566 for 20 min reduced Fsk induction of IL-6 mRNA
by 48.21% (Figure 3-9). The effect of SQ22,536 pretreatment on IL-6 promoter activity
was measured by luciferase assay. SQ22,536 did not significantly reduce Fsk-induced
IL-6 promoter activity when the inhibitor was added at 1, 3, or 10 µM for 30 min prior to
Fsk treatment (Figure 3-10).
IL-6 basal expression and induction by Fsk differ in BSMC from an asthmatic
donor
IL-6 levels in BALF and serum are increased in patients with asthma, and BSMC
could be one contributor to raised IL-6 levels (Rincon and Irvin 2012). We
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Figure 3-6. Time course of Fsk-induced IL-6 mRNA expression
qRT-PCR was used to measure IL-6 mRNA expression in control BSMC exposed to
1 µM Fsk for the indicated time. Data are expressed as the inverse of the CP, mean ±
SEM, n=2-3.
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Figure 3-7. Fsk-induced IL-6 mRNA expression and protein production in AC
overexpressing BSMC
(A) qRT-PCR was used to detect IL-6 mRNA levels in BSMC exposed to 1 µM Fsk for
1 h. mRNA levels of Fsk-treated cells are expressed as fold change with respect to lacZ
basal, mean ± SEM, n=3. Dashed line represents no change with respect to lacZ basal.
* indicates p<.05 compared to lacZ. (B) ELISA were used to measure IL-6 secreted into
culture medium by BSMC treated with 1 µM Fsk for 24 h. Data are presented % change
with respect to lacZ basal, mean ± SEM, n=3. * indicates p<.05 compared to lacZ basal.
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Figure 3-8. Time course of Fsk-stimulated IL-6 protein production
ELISA were used to measure IL-6 protein in cell culture medium following exposure to
1 µM Fsk for the indicated amount of time. Mean ± SEM, n=1-2.
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Figure 3-9. Inhibition of Fsk-induced IL-6 expression with AC2-selective
inhibitor
qRT-PCR was used to determine IL-6 mRNA levels in BSMC pretreated with 30 µM
SKF-83566 or vehicle for 20 min prior to 1 h, 1 µM Fsk treatment. mRNA levels are
expressed relative to vehicle treated, mean ± SEM, n=4. Dashed line represents no
change with respect to vehicle. * indicates p<.05 compared to Fsk alone.
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Figure 3-10. Inhibition of Fsk-induced IL-6 promoter activation with AC6selective inhibitor
Luciferase assays were used to determine IL-6 promoter activation in BSMC pretreated
with the indicated concentration of SQ22,536 or vehicle for 30 min prior to 6 h, 1µM Fsk
treatment. Luminescence is expressed relative to vehicle treated, mean ± SEM, n=4.
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wondered if cAMP-mediated IL-6 induction differed in BSMC from an asthmatic donor
compared to a non-asthmatic donor. Cells from different donors were cultured in
identical growth medium with the intent to uncover any intrinsic changes in IL-6
induction pathways in asthmatic BSMC. BSMC from an asthmatic donor had basal
levels of IL-6 mRNA that were 3-times higher than BSMC from a non-asthmatic donor
(Figure 3-11). When BSMC from the asthmatic donor were treated with 1 µM Fsk, there
was no increase in IL-6 mRNA compared to those cells untreated. In non-asthmatic
BSMC treated at the same time, Fsk treatment caused a 2.6-fold increase in IL-6 mRNA
levels. IL-6 expression is increased in asthmatic BSMC at rest, and AC activation by Fsk
is unable to further stimulate IL-6 transcription as it does in healthy BSMC.
Discussion
A number of genes that are differentially regulated by individual AC isoforms in
BSMC and HEK-293 were identified by PCR array (Figures 3-1 and 3-2). In BSMC
IL-6 is selectively regulated by AC2 and SST is selectively regulated by AC6. AC
isoform-specific enhancement of the induction of these genes results in increased protein
production (Figures 3-5 and 3-7B). Basal expression of IL-6 is increased in asthmatic
BSMC, and induction by Fsk is impaired (Figure 3-11).
Cell-type differences
BSMC are highly differentiated cells with unique physiological roles. To confirm
that AC isoform-specific regulation of gene expression is a generalizable phenomenon,
we also tested the less well differentiated HEK-293 cells. Both cell types have cAMP
regulated genes and genes that are differentially regulated when specific AC isoforms are
overexpressed (Figures 3-1 and 3-2). Interestingly, the AC isoforms that are
predominately expressed in these cell types are similar, but the degree of
compartmentation differs greatly. It is not surprising that cAMP stimulates different
genes in cell types with distinct physiological roles.
One methodological difference in these studies is the mode of AC overexpression.
BSMC have poor transfection efficiency, whether using lipofectamine or calcium
phosphate transfection methods. Therefore adenoviral vectors were used to overexpress
proteins of interest in BSMC. β galactosidase staining indicates lacZ expression in
greater than 90% of BSMC following adenoviral mediated gene transfer (Bogard et al.
2011). HEK-293 efficiently take up plasmids when transfected, but adenoviral
overexpression cannot be used in HEK-293. They cannot be infected with adenovirus to
overexpress AC because they are packaging cells that contain the E1 and E3 adenoviral
genes, which allow adenoviral replication and lysing of the cells.
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Figure 3-11. Fsk induction of IL-6 in normal and asthmatic BSMC
qRT-PCR was used to detect mRNA levels in BSMC exposed to 1 µM Fsk for 1 h.
mRNA levels are expressed as fold change with respect to normal basal, mean ± SEM,
n=3.
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IL-6 and asthma pathogenesis
The finding that AC2 specifically regulates expression of the pro-inflammatory
cytokine IL-6 in BSMC is of particular interest due to its role in the pathogenesis of
asthma. IL-6 is increased in the serum and BALF of asthmatic patients and is inversely
correlated with lung function (Neveu et al. ; Morjaria et al. 2011). IL-6 is more than just
a marker of inflammation in asthma. It can be secreted by structural cells independent of
inflammation and plays a role in the development and worsening of pathological changes
associated with asthma (Rincon and Irvin 2012). IL-6 has many effects in the airway.
The main targets of IL-6 are immune cells, but soluble IL-6 receptors and trans-signaling
allow IL-6 to mediate responses in most cell-types (Rose-John et al. 2006). IL-6
encourages the differentiation of CD4+ T cells to Th2 cells and inhibits maturation of Th1
cells (Diehl and Rincon 2002). This bias toward Th2 is likely involved in many
pathological features of asthma including inflammation, mucus secretion, and airway
hyper-responsiveness (Georas et al. 2005). IL-6 increases airway resistance and causes
smooth muscle hypertrophy and hyperplasia in rodents (De et al. 1995; Rubini 2010).
IL-6 is obviously important in asthma pathology, and treatment with βAR agonists may
be increasing IL-6 production through AC2-mediated signaling. A better understanding
of the cAMP signaling compartments associated with regulating IL-6 expression could
allow for more precisely targeted asthma therapies in the future.
We found that IL-6 expression was increased in BSMC from an asthmatic donor
compared to cells from a healthy donor under basal conditions. BSMC from the
asthmatic donor did not respond to Fsk with increased IL-6 expression as the normal
BSMC did. The lack of Fsk response could be explained by the high basal IL-6
expression. If the pathways responsible for induction of IL-6 are constitutively active in
asthmatic BSMC, Fsk may not have a further effect. Figure 3-11 represents data
gathered from multiple treatments of cells isolated from 2 donors. The data here do not
allow us to draw conclusions about difference between asthmatic and non-asthmatic
BSMC, because they are only from a single asthmatic and a single non-asthmatic donor.
IL-6 induction by cAMP signaling in BSMC from asthmatic and non-asthmatic donors
should be repeated with cells from additional donors before conclusions can be made.
AC isoform differences
We show that genes can be regulated differently by individual AC isoforms. In
BSMC AC2, AC4, and AC6 are endogenously expressed, and we have shown that AC2
and AC6 have distinct effects on expression of various genes when they are
overexpressed and activated in BSMC. AC3 was included in our study to represent
group I AC, and it was not associated with changes in Fsk-mediated gene regulation
compared to control BSMC. With IL-6 found to be specifically regulated by AC2derived cAMP, the rest of this project focused on uncovering the signaling pathways
involved to determine how AC2- but not AC6-derived cAMP is associated with induction
of IL-6.
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CHAPTER 4.

RECEPTOR MEDIATED IL-6 INDUCTION IN BSMC
Introduction

There are over 800 genes encoding GPCR in the human genome (Fredriksson et
al. 2003). Patterns of receptor expression are dependent on cell type, and most cells
express many different GPCR (Hakak et al. 2003). Activities of more than 20 GPCR
have been described in BSMC, with at least 5 different receptors coupling to Gαs
(Billington and Penn 2003). Since receptors contribute to compartmentation due to
differences in their associations with AC isoforms, we hypothesized that only a subset of
receptors in BSMC would be linked to induction of IL-6. Many different receptor types
have been implicated in IL-6 induction in various cell types. Among the Gαs-coupled
receptors that have been linked to IL-6 induction in other cells are β2AR, β3AR, EP2R,
tachykinin, CGRP, adenosine A2B, and purinergic receptors (Chen et al. 2012;
Tchivileva et al. 2009; Fiebich et al. 2000; Millet and Vignery 1997; Wang et al. 2010;
Zhong et al. 2005; Inoue et al. 2007). If expressed in the right signaling compartment,
these Gαs-coupled receptors have the potential to induce IL-6 in BSMC.
One way that AC isoforms differentially regulate cellular responses is through
isoform-specific associations with receptors (Ostrom et al. 2000c). Colocalization in
specialized membrane microdomains can promote specific AC-receptor interactions.
Lipid rafts are specialized domains within the plasma membrane with high levels of
cholesterol and sphingolipids. Caveolae represent a subset of lipid rafts distinguishable
by their flask-like shape and expression of caveolin proteins. Interactions with
membrane lipids or proteins allow enrichment of certain signaling molecules in lipid rafts
while others are excluded (Ostrom and Insel 2004). The content of caveolae is dynamic
and translocation can alter the regulation and responses of signaling molecules (Ostrom et
al. 2001; Rybin et al. 2000). There are likely several mechanisms acting to target specific
proteins to lipid rafts and caveolae, including protein-lipid interactions, protein-protein
interactions and post-translational modifications (Moffett et al. 2000; Resh 2006; Hnasko
and Lisanti 2003). Cell-specific differences in localization of receptors and AC have
been observed for both native and overexpressed protein, providing an additional
mechanism for cell-specific cAMP-mediated responses (Ostrom et al. 2000c; Ostrom et
al. 2002). Colocalization in lipid rafts facilitates specific receptor-AC associations and
interactions with downstream effectors and is likely responsible for some receptorspecific and AC isoform-specific cellular responses (Pike 2003).
Particular GPCR-AC associations have been described in a number of different
cells, including BSMC. βAR and AC6 are colocalized and interact in caveolae in
neonatal cardiac myocytes, and a number of other receptors do not have access to AC6 in
this compartment (Ostrom et al. 2000c). In BSMC AC6 and β2AR colocalize in
caveolae, while AC2 and AC4 are excluded from them. EP2R colocalize and interact
with AC2/AC4 outside of lipid rafts and cannot stimulate AC6 (Bogard et al. 2011).
Specific GPCR-AC coupling can also occur through direct protein-protein interactions or
AKAP-organized complexes (Lavine et al. 2002; Dessauer 2009). Due to specific
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localization and interactions of GPCR with AC and downstream effectors, we
hypothesized that not all Gαs coupled receptors are associated with AC2 and tied to
induction of IL-6 expression. We examined expression of GPCR in BSMC and used
specific agonists to activate GPCR to determine which receptors stimulate IL-6
production.
Results
Receptor-mediated induction of IL-6 is enhanced specifically by AC2
After finding that direct activation of AC with Fsk resulted in an induction of IL-6
that was enhanced specifically by AC2 overexpression and not other AC isoforms, we
wanted to determine if AC2 specificity persists when IL-6 is induced by activation of
Gαs-coupled receptors. We hypothesized that colocalization of receptors, AC, and
downstream effectors create distinct cAMP signaling compartments in BSMC. We have
previously shown that AC2 and EP2R are excluded from lipid rafts in BSMC, and that
β2AR are predominately localized to lipid rafts where they colocalize with AC6 (Bogard
et al. 2011). These receptors have also been shown to induce IL-6 expression in other
cell-types (Chen et al. 2012; Fiebich et al. 2001). Thus, we stimulated β2AR with
isoproterenol (Iso) or EP2R with butaprost (Buta) for 24 h and measured IL-6 mRNA by
qRT-PCR and IL-6 secreted into culture supernatant by ELISA.
Iso and Buta were both able to induce IL-6 expression in BSMC. In control and
AC overexpressing cells these agonists caused a significant increase in IL-6 mRNA
(Figure 4-1). AC2 overexpression significantly enhanced IL-6 mRNA production in Iso
treated cells compared to cells expressing only native levels of AC. Since the effect of
Buta on IL-6 induction was highly variable, AC2’s effect did not reach statistical
significance. AC6 overexpression did not change RNA levels compared to control cells
in response to any of the agonists tested.
Treatment with Iso or Buta also increased IL-6 protein in an AC2-specific manner
(Figure 4-2). Unlike mRNA, these agonists did not significantly increase IL-6 protein
compared to vehicle in control cells. Only in AC2 overexpressing cells did Iso and Buta
treatments result in significant increases in IL-6 production. AC2 overexpression
enhanced IL-6 protein production in response to Iso compared to control cells. As with
mRNA studies, variability in the response to Buta prevented a statistically significant
enhancement in AC2 overexpressing cells. AC6 overexpression did not alter IL-6 protein
levels compared to control cells with endogenous AC expression in any of the conditions
tested.
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Figure 4-1. IL-6 mRNA expression in response to GPCR agonists
qRT-PCR was used to determine IL-6 mRNA levels in BSMC overexpressing lacZ, AC2
or AC6 treated with 1 µM of the indicated drug for 1 h. mRNA levels are expressed
relative to lacZ basal, mean ± SEM, n=6. * indicates p<.05 compared to basal in lacZ, #
indicates p<.05 in AC overexpressing cells compared to same treatment in control cells.
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Figure 4-2. IL-6 protein production in response to GPCR agonists
ELISA were used to determine IL-6 protein levels in culture medium from BSMC
overexpressing lacZ, AC2 or AC6 treated with 1 µM of the indicated drug for 24 h.
Dashed line indicates no change with respect to lacZ basal. IL-6 protein is expressed
relative to lacZ basal, mean ± SEM, n=3. * indicates p<.05 compared to lacZ basal, #
indicates p<.05 in AC overexpressing cells compared to same treatment in control cells.
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BSMC express several GPCR
GPCR expression is cell-type dependent and most cells express many different
receptors. The full complement of receptors expressed in BSMC has not been described
previously. To better understand how AC2 specifically enhances IL-6, we wanted to
know whether all Gαs-coupled GPCR, or only a subset, are able to stimulate IL-6 gene
expression. To determine which GPCR are expressed in BSMC, we used PCR arrays to
probe for mRNA of 370 receptors (Table A-3). Following amplification, SYBR green
melt curves were analyzed, and genes with more than one peak were excluded due to the
ambiguity associated with multiple products. It is important to note that the PCR array
data are qualitative in this context. Since cDNA for each receptor was amplified with
different primers resulting in products of varying lengths, receptors with lower CP values
are not necessarily expressed at higher levels. The PCR array served as a starting point to
discover all the GPCR expressed by BSMC, but ultimately other approaches must be
used to confirm functional receptor expression. mRNA was detected (CP <35) for 227 of
the receptors tested, while mRNA was not detected (CP >35) for 81 receptors
(Table A-3).
The PCR array detected mRNA for β2AR, with an average CP of 29.90.
Amplification by EP2R primers was also apparent (CP: 26.59), but since there were
multiple peaks on the melt curve the data were not conclusive, and this receptor was not
included in Table A-3. EP2R expression in BSMC has been confirmed by other methods.
EP2R immunoblots and the ability of Buta, an EP2R-selective agonist, to increase cAMP
and IL-6 (Figure 4-1) indicate that this receptor is expressed in BSMC (Bogard et al.
2011). The CP of other receptors potentially associated with IL-6 induction are listed in
Table 4-1 with their predominant G-protein associations and the agonists used to
investigate their activity in BSMC.
Not all receptors are associated with induction of IL-6
We chose a subset of the receptors with readily detectible mRNA and measured
cAMP and IL-6 production following stimulation with specific agonists (Table 4-1).
IL-6 protein in culture medium increased compared to vehicle following 24 h treatment
with a purinergic receptor agonist, ATPƔS, or adenosine receptor agonist, 5'-Nethylcarboxamidoadenosine (NECA, Figure 4-3A). Arginine vasopressin (AVP), BRL
37344 (β3AR-selective agonist), α-calcitonin gene related peptide (α-CGRP), glucagon,
prostaglandin D2 (PGD2), and substance P did not significantly increase IL-6 secretion
compared to vehicle (Figure 4-3A).
We also tested these agonists for their ability to stimulate cAMP production in
BSMC. Cells were treated with the same GPCR-selective agonists for 10 min in the
presence of a broad-spectrum PDE inhibitor (0.2 mM IBMX). ATPƔS and NECA,
agonists that increased IL-6 secretion, did not significantly increase global cAMP levels
(Figure 4-3B). The cAMP response to NECA may be blunted by antagonism of
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Table 4-1.

GPCR agonists and their targets in BSMC

Agonist

Receptor

Activity

Affinity

G-protein

CP

ATPƔS

P2Y12

Full
agonist

5.5a

Gi/Go

40

ATPƔS

P2Y11

Full
agonist

4.9 – 5.5b

1˚: Gq/G11
2˚: Gs

29.13

ATPƔS

P2Y1

Partial
agonist

7.4c

1˚: Gq/G11
2˚: Gi/Go

34.49

ATPƔS

P2Y13

Full
Agonist

5.5c

Gi/Go

33.92

AVP

Vasopressin
V1B

Full
agonist

9.0 – 9.5 a

Gq

31.00

AVP

Vasopressin
V1A

Full
agonist

8.5 – 9.3 a

Gq/G11

31.63

AVP

Vasopressin V2

Full
agonist

7.9 – 9.1 a

Gs

33.55

AVP

OT Receptor

Partial
agonist

7.3 – 9.3 a

Gi/Go

27.42

BRL
37344

β3 Adrenergic

Full
agonist

6.4 – 7a

1˚: Gs
2˚: Gi/Go

30.96

αCGRP

AM1

Full
agonist

6.0d

1˚: Gs
2˚: Gi/Go,
Gq/G11

RAMP2
: ND
CALCR
L: 31.76

αCGRP

CGRP

Full
agonist

9.7 – 10 a

1˚: Gs
2˚: Gi/Go,
Gq/G11

RAMP1
: ND
CALCR
L: 31.76

32

Table 4-1.

(Continued)

Agonist

Receptor

Activity

Affinity

αCGRP

AM2

Full
agonist

6.5 – 6.8 a

αCGRP

AMY1

Full
agonist

8.7 – 10.8b Gs

RAMP1
: ND
CALCR
: 36.08

αCGRP

AMY3

Full
agonist

7.6 – 9.7b

Gs

RAMP3
: ND
CALCR
: 36.08

αCGRP

AMY2

Full
agonist

6.2 – 9.7b

Gs

RAMP:
ND
CALCR
: 36.08

αCGRP

CT

Full
agonist

6.2 – 8.4b

1˚: Gs
2˚: Gq/G11

36.08

Glucagon

GLP-1

Full
agonist

6.9 – 7 a

Gs

ND

Glucagon

Glucagon

Full
agonist

9.0 b

Gs

34.68

NECA

A3

Full
agonist

7.5 – 8.4 a

Gi

38.79

NECA

A2A

Full
agonist

6.9 – 8.7 a

1˚: Gs
2˚: Gq/G11

32.47

NECA

A1

Full
agonist

5.3 – 8.2 a

1˚: Gi/Go
2˚: Gs
Gq/G11

32.01
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G-protein
1˚: Gs
2˚: Gi/Go,
Gq/G11

CP
RAMP3
: ND
CALCR
L: 31.76

Table 4-1.

(Continued)

Agonist

Receptor

Activity

Affinity

G-protein

CP

NECA

A2B

Full
agonist

5.7 – 6.9 a

1˚: Gs
2˚: Gq/G11

27.61

PGD2

EP4

Full
agonist

8.7 – 9 a

1˚: Gs
2˚: Gi/Go

27.71

PGD2

DP1

Full
agonist

7.8 – 9.2 a

Gs

32.92

PGD2

DP2

Full
agonist

7.6 – 8.6 a

Gi/Go

ND

PGD2

FP

Full
agonist

7.7 a

1˚: Gq/G11
2˚: Gs

28.38

PGD2

EP2

Full
agonist

5.0 a

Gs

26.59

PGD2

EP1

Full
agonist

4.7 a

1˚: Gq/G11
2˚: Gi/Go

31.82

Substance NK1
P

Full
agonist

8.5 – 10.3 a

Gs,
Gq/G11

34.49

Substance NK2
P

Full
agonist

5.9 – 6.9 a

Gs,
Gq/G11

32.78

Substance NK3
P

Full
agonist

5.0 – 6.0 a

Gq/G11

32.75

Notes: Affinities are listed as a, pKi; b, pEC50; c, pIC50; d, pKd. Some receptors can
couple to multiple G-proteins. 1˚ represents the primary coupling and 2˚ represents
secondary coupling. ND (not determined) indicates genes that were not tested.
Source: Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V,
Davenport AP, Peters JA, Spedding M, Harmar AJ, Nc I (2013) IUPHAR-DB: updated
database content and new features. Nucleic Acids Res 41 (Database issue):D1083-1088.
doi:10.1093/nar/gks960
.
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Figure 4-3. cAMP and IL-6 protein production in response to Gαs-coupled
receptor agonists
BSMC were treated with 1µM Fsk, AVP, CGRP, glucagon, PGD2, substance P; 10 µM
ATPƔS, BRL 37344, NECA. (A) ELISA were used to measure IL-6 secreted into culture
media from cells treated with the indicated drug for 24 h. (B) cAMP was measured by
EIA in BSMC that were pretreated with 0.2 mM IBMX prior to 10 min agonist. Dashed
line represents no change with respect to vehicle. Data are presented as the fold response
over vehicle, mean ± SEM, n=3-4. * indicates p<.05 compared to vehicle.
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adenosine receptors by IBMX (Daly et al. 1987). BRL 37344 and glucagon, agonists that
did not increase IL-6 production, induced small but non-significant cAMP responses.
IL-6 and cAMP levels are not directly correlated
Since levels of IL-6 production did not appear to directly correlate with global
cAMP levels, we further examined the correlation between cAMP and IL-6 using
agonists for β2AR and EP2R, receptors whose expression in BSMC and ability to
stimulate IL-6 in other cell types have been well described (Bogard et al. 2011;
Raychaudhuri et al. 2010; Chen et al. 2012). Simultaneous Gαs and Fsk stimulation
produces a synergistic cAMP response in many cell types that can aid in determining the
role of this signaling pathway (Insel and Ostrom 2003; Daly et al. 1982; Darfler et al.
1982; Sutkowski et al. 1994; Ostrom et al. 2000a). AC2 overexpressing cells were
treated with 0.1 µM Iso or Buta alone and with concurrent Fsk (0.1 µM) treatment to
determine if increased cAMP always translates to increased IL-6 production. Lower
concentrations of each drug were used in order to observe synergistic effects. Addition
of Fsk at the time of Buta stimulation significantly increased cAMP production over
agonist alone (Figure 4-4A). High variability in Iso-treated cells resulted in a non
significant effect of Fsk, but addition of Fsk consistently resulted in at least doubling of
cAMP compared to Iso alone. Thus, BSMC express a moderate Gαs-Fsk synergistic
effect. Using these same conditions, we found no increase in IL-6 production
(Figure 4-4B). Simultaneous Gαs and Fsk stimulation increases cAMP substantially, but
the cAMP increase does not translate to greater IL-6 expression. cAMP induces IL-6
expression in BSMC, but the levels of cAMP and IL-6 are not directly correlated.
Discussion
Agonists that do not have a significant effect on cAMP levels can induce IL-6
(Figure 4-3). Even with PDE inhibition, ATPγS and NECA did not significantly
increase cAMP production over basal levels. These two agonists can activate GPCR
coupled to Gαq pathways in addition to Gαs. Gαq initiates protein kinase C (PKC) and
mitogen activated protein kinase (MAPK) signaling pathways, which have been shown to
induce IL-6 expression in other cell types. Additionally, PKC regulates AC activity of
some isoforms. PKC can activate AC2, even without stimulation by Gαs or Fsk
(Jacobowitz and Iyengar 1994). The ability of ATPγS and NECA to stimulate IL-6
production without significantly increasing cAMP could be through Gαq activated PKC
directly activating AC2, or via PKC signaling pathways themselves.
Surprisingly Iso and Buta, agonists targeting receptors that are known to be
expressed in BSMC and capable of inducing IL-6 expression, did not significantly
increase protein production in control cells. With this known, the other agonists would
have been better tested in AC2 overexpressing cells, or had their ability to induce mRNA
expression measured instead of protein. We cannot be certain that the agonists that did
not show increased protein are not associated with induction of IL-6 gene expression.
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Figure 4-4. cAMP and IL-6 production in BSMC by GPCR agonists alone or with
concurrent Fsk treatment
(A) Cells were treated with 0.1 µM of the indicated drug with or without concurrent
treatment with 0.1 µM Fsk for 10 min in the presence of 0.2 mM IBMX. cAMP was
measured by EIA. (B) Cells were treated with 0.1 µM of the indicated drug with or
without concurrent treatment with 0.1 µM Fsk. IL-6 in culture media was measured by
ELISA following 24 h drug treatment. Dashed line represents no change with respect to
basal. Data in both panels are presented as the fold over vehicle, mean ± SEM, n=3.
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The agonists BRL-37344, substance P, and CGRP stimulate IL-6 production in
other cells, but they did not increase IL-6 protein production in BSMC (Figure 4-3)
(Tchivileva et al. 2009; Millet and Vignery 1997; Wang et al. 2010). There are cell-type
differences in receptor-mediated induction of IL-6, likely due to differences in receptor
expression, signaling intermediates and signaling compartments of cells. Gαs-coupled
receptors β2AR and EP2R are linked to IL-6 induction in BSMC (Figure 4-1). As
expected based on Fsk responses AC2 derived-cAMP selectively induces IL-6 in
response to GPCR stimulation. Not all Gαs receptors are associated with induction of IL6, likely in part due to localization that places them apart from AC2. In addition to
colocalization, we found that differences in regulation, particularly AC2 activation by
PKC, could be involved in some of the GPCR-mediated IL-6 induction downstream of
AC2.
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CHAPTER 5.

DOWNSTREAM SIGNALING AND PROMOTER ELEMENTS
ASSOCIATED WITH cAMP INDUCTION OF IL-6
Introduction

cAMP induces IL-6 through various signaling pathways, with differences among
cell types. The intermediate signaling molecules linking cAMP to IL-6 induction have
not been studied in BSMC. In astrocytes, PGE2 enhances IL-6 expression through
Gαs-coupled EP4-like receptors and p38 MAPK and PKC pathways (Fiebich et al. 2001).
In chondrocytes the same stimulus regulates IL-6 expression through PKA and
phosphatidylinositol 3-kinase (PI3K) pathways (Wang et al. 2010). IL-6 induction by
βAR activation in neonatal mouse cardiac fibroblasts is Epac-dependent and involves
PKCδ and p38 MAPK signaling pathways (Chen et al. 2012). Since it is clear that
pathways mediating cAMP induction of IL-6 are cell-type specific, we sought to
determine which signaling intermediates are required for Fsk-induced IL-6 expression in
BSMC.
cAMP can regulate gene expression through several different signaling pathways
and a variety of transcription factors, and by the time the signal has reached the nucleus
there are many opportunities for crosstalk among various signaling pathways. The IL-6
promoter contains C/EBP, CRE, NF-κB, and 2 AP-1 sites (Dendorfer et al. 1994; Akira et
al. 1990; Tanabe et al. 1988). Pathways initiated by cAMP have the potential to regulate
transcription factor and cofactor binding at each of these sites. The most direct pathway
linking cAMP to gene induction is through PKA phosphorylation of CREB bound to the
CRE site (Gonzalez and Montminy 1989). CREB is bound to chromatin under
unstimulated conditions, but PKA phosphorylation at Ser 133 leads to binding of CREB
binding protein (CBP) and recruitment of transcription initiation complexes (Montminy
1997). PKA is not the only kinase that phosphorylates CREB at Ser 133, so other
pathways can also regulate transcription initiation at CRE (Shaywitz and Greenberg
1999). AP-1 sites have a consensus sequence that is closely related to the CRE sequence,
and CREB can also regulate transcription at these sites (Lee et al. 1987; Lamph et al.
1990). Transcription at AP-1 is also initiated by Fos-Jun dimers, which are activated by
MAPK signaling cascades (Karin 1996).
NFκB is involved in induction of many inflammatory genes. It is sequestered in
the cytosol by IκB and translocates to the nucleus following phosphorylation of IκB by Iκ
kinase (IκK). IκK can be activated by any of the pathways that have been implicated in
IL-6 induction in other cell types (Hayden and Ghosh 2008). The transcription factor
C/EBP is also known as NF-IL-6 (Akira et al. 1990). Most cells express multiple C/EBP
isoforms with varying activity. cAMP induces C/EBP translocation to the nucleus (Metz
and Ziff 1991). Interestingly, asthmatic ASM do not express C/EBPα, an inhibitory
isoform (Roth et al. 2004). The C/EBP site does not appear to be involved in cAMPmediated IL-6 expression, but it may play a role in increased proliferation of ASM in
asthma (Roth et al. 2004). AC isoform-specific localization and interactions are involved
in establishing distinct cAMP signaling compartments that regulate precise cellular
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responses. We looked downstream of cAMP to uncover the signaling intermediates
responsible for transduction of the signal from AC2 to the IL-6 promoter. We used
selective cAMP agonists and inhibitors of intermediate kinases and found that PKA and
Epac are activated downstream of AC2 and stimulate IL-6 induction via CRE and AP-1
promoter elements.
Results
PKA and Epac signaling induce IL-6 production
To determine what makes AC2-derived cAMP specifically linked to induction of
IL-6, we examined the downstream signaling pathways that connect cAMP signals to the
nucleus. cAMP transduces signals through activation of PKA and Epac. Using specific
cAMP analogs we probed for the role of each of these downstream effector molecules in
regulating IL-6 levels. Exposure to 1 µM 8CPT-2Me-cAMP or 8-Br-cAMP did not
significantly increase IL-6 protein secretion over vehicle (Figure 5-1). The Epac
selective analog, 8CPT-2Me-cAMP, significantly increased IL-6 protein at 10 µM and
100 µM, increasing IL-6 by slightly over 50% at both concentrations. At 10 µM the nonselective analog, 8-Br-cAMP, produced a similar response to 8CPT-2Me-cAMP.
However, treatment with 100 µM 8-Br-cAMP led to a substantially larger response than
the Epac selective analog, with a 4-fold increase in IL-6 protein over vehicle. The typical
response to 1 µM Fsk resulted in IL-6 levels greater than any 8CPT-2Me-cAMP
concentration and comparable to an 8-Br-cAMP concentration between 10 µM and
100-µM.
To determine if PKA activity is required for induction of IL-6 in response to Fsk,
we pretreated cells with the PKA inhibitor H-89. PKA inhibition reduced IL-6 produced
in response to 1 µM Fsk by 13.4% (Figure 5-2). When treated with selective cAMP
analogs, PKA had a greater role in regulating induction of IL-6 when cAMP levels were
high. Increasing the Fsk concentration to 10 µM did not result in any greater reduction of
IL-6 production by H-89 (Figure 5-2). 10 µM Fsk produces maximal cAMP production
in BSMC, but the intracellular cAMP levels are probably not as high as treatment with
100 µM 8-Br-cAMP. Epac and PKA are responsible for cAMP-mediated induction of
IL-6. PKA produces large increases in IL-6 in response to high cAMP levels, but Epac
appears to regulate much of the IL-6 expression induced by Fsk treatment.
Inhibition of PKC, p38 MAPK, or PI3K does not block Fsk induction of IL-6
We used inhibitors of PKC (GF 109203X), p38 MAP kinase (SB 202190), or
PI3K (wortmanin) to probe for the role of these signaling pathways, since work in other
cell types implicates them in Gαs-mediated induction of IL-6 (Fiebich et al. 2001; Wang
et al. 2010). BSMC were pretreated for 1 h with 10 µM of each inhibitor, concentrations
that significantly inhibited IL-6 expression in other cell types (Fiebich et al. 2001;
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Figure 5-1. IL-6 protein production induced by cAMP analogs
ELISA were used to measure IL-6 protein in the culture medium of BSMC following
24 h treatment with the indicated concentration of 8-Br-cAMP or 8CPT-2Me-cAMP.
Dashed line represents no change with respect to vehicle. Data are presented relative to
vehicle, mean ± SEM, n=4. * indicates p<.05 compared to vehicle, # indicates p<.05
compared to 8CPT-2Me-cAMP.
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Figure 5-2. IL-6 protein production by Fsk in the presence of PKA inhibitor
ELISA were used to measure IL-6 in culture supernatant of cells pretreated with 3 µM
H-89 or vehicle prior to 24 h 1 µM Fsk. Dashed line represents no change with respect to
vehicle. Data are presented relative to vehicle, Mean ± SEM, n=4. * indicates p<.05
compared to Fsk alone.
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Wang et al. 2010). Following inhibitor pretreatment, cells were exposed to 1 µM Fsk for
1 h, and IL-6 mRNA expression was measured by qRT-PCR. None of the inhibitors
tested had a significant inhibitory effect on Fsk-stimulated IL-6 expression (Figure 5-3).
In fact, GF 109203X or wortmanin pretreatment tended to increase IL-6 production
compared to Fsk alone (not significant). Since nonspecific effects could occur at the
concentrations we chose, we tested each inhibitor at concentrations ranging from 10 nM
to 10 µM. There was no inhibition of Fsk-induced IL-6 expression by this range of
concentrations by any of the inhibitors tested (data not shown). If anything, these
inhibitors slightly increased Fsk-induced IL-6 expression. cAMP-mediated regulation of
IL-6 expression may involve multiple stimulatory and inhibitory pathways with
substantial cross talk and redundancy, making it difficult to unravel the steps with
inhibition of individual intermediate kinases.
Activation of the IL-6 promoter by Fsk requires AP-1 and CRE sites
We used promoter analysis as an alternative approach to determine the signaling
pathways involved in cAMP-mediated IL-6 expression. BSMC were transfected with
vectors containing 1168 base pairs of the wild type human IL-6 promoter driving
expression of the luciferase reporter gene. We also utilized individual promoter-reporter
constructs that contained mutations in each of the defined promoter elements in order to
test which transcriptional site(s) are required for cAMP-mediated expression of IL-6.
The IL-6 promoter contains 2 AP-1 sites and 1 CRE, C/EBP and NFκB site. Site directed
mutagenesis prevented transcription factor binding at the indicated site. Mutagenesis of
the 3’ AP-1 site increased IL-6 production in vehicle- and Fsk-treated BSMC, possibly
due to regulation by a repressor at this site in the wild type promoter (Figure 5-4).
Promoter activity was unchanged in the other mutant constructs under basal conditions.
When stimulated with 1 µM Fsk, luciferase activity was significantly reduced when the
5’AP-1 or CRE site was mutated as compared to the wild type promoter (Figure 5-4).
Mutations to C/EBP or NF-κB did not alter the promoter’s response to Fsk . For cAMP
induction of IL-6 in BSMC, 5’AP-1 and CRE sites are essential but C/EBP and NFκB
sites are not involved.
Discussion
At lower cAMP concentrations, Epac-selective and non-selective cAMP analogs
have similar effects on IL-6 protein production (Figure 5-1). At higher cAMP
concentrations, Epac does not contribute to any additional IL-6 response, but PKA
signaling has a large effect on inducing IL-6 production. These data indicate a high
affinity but low efficacy Epac component and a lower affinity but higher efficacy
contribution from PKA activity. Stimulation by 1 µM Fsk likely produces intermediate
cAMP levels that act through both Epac and PKA to induce IL-6 expression. PKA
inhibition with H-89 resulted in a small reduction of IL-6 protein in response to 1 µM or
10 µM Fsk (Figure 5-2), consistent with dual pathways employing Epac or PKA.
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Figure 5-3. Fsk-induced IL-6 expression in the presence of kinase inhibitors
qRT-PCR was used to measure IL-6 mRNA in BSMC pretreated with 10 µM of the
indicated inhibitor prior to 1 µM, 1 h Fsk exposure. Data are expressed relative to
vehicle, mean ± SEM, n=3-4.
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Figure 5-4. Promoter activity of wild type and mutant IL-6 promoter constructs
Luciferase assays were used to measure promoter activity in BSMC transfected with wild
type or mutant promoter constructs and exposed to 1 µM Fsk or vehicle for 6 h. Wild
type is 1168 base pairs of the human pIL-6 promoter. Each promoter mutant construct is
named by the binding site that has been ablated by site directed mutagenesis. Data are
expressed as luminescence relative to wild type basal, mean ± SEM, n=11. * indicates
p<.05 compared to wild type.
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The kinase inhibitors that we used to try to understand the signaling intermediates
involved did not reduce Fsk-induced IL-6 expression in BSMC (Figure 5-3). It is
possible that some other pathway is responsible for activating IL-6 expression, or the
inhibitors that were effective in other cell types may not be appropriate for inhibiting
these pathways in BSMC. By the time the signal has been passed from the plasma
membrane to the nucleus there are many chances for cross-talk and redundancy of
pathways, and inhibition at a single point may not be enough to prevent induction.
Another pitfall is that inhibitors are not highly selective. An alternative approach to
pharmacological inhibitors is RNA interference, which could produce specific inhibition
without off-target effects. The poor transfection efficiency of BSMC limits the utility of
RNAi in the present studies. We found that PKA and Epac are involved in cAMPmediated induction of IL-6 in BSMC, but have little insight into the downstream effectors
that are involved in the signal transduction pathways leading to activation of transcription
at CRE and AP-1 promoter sites.
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CHAPTER 6.

FINAL DISCUSSION AND FUTURE DIRECTIONS
AC Isoform-Specific Responses

This work represents the first demonstration of AC isoform-specific control of
gene regulation. Previous studies have defined cAMP signaling compartments in nearmembrane events or regulation of proximal intracellular signals, but no other work of
which we are aware has demonstrated cAMP compartments regulating specific genes.
AC2 contributes to a signaling compartment that selectively induces IL-6 in BSMC.
AC6-derived cAMP is involved in regulation of other genes, including SST, which it
selectively regulates, but it does not influence IL-6 expression. Differences in AC
regulation, localization, and associations with other proteins allow AC isoforms to create
unique cAMP pools with diffusion constrained by activity of PDE. Through activation of
Epac and PKA, cAMP produced by AC2 signals to the nucleus and induces IL-6
expression via CRE and AP-1 promoter elements.
Inherent differences in regulation of AC2 and AC6 could be one contributor to
AC2 selective IL-6 enhancement. AC2 is activated by PKC, but AC6 is inhibited by this
kinase (Jacobowitz and Iyengar 1994; Lai et al. 1999). The ability of ATPɣS and NECA
to induce IL-6 without significant global cAMP increase (Figure 4-3) could be explained
by activation of Gαq-coupled receptors, which stimulate a direct PKC activation of AC2.
These molecules may all exists as part of a complex with AKAP79 as recently described
by Shen and Cooper (2013). Using plasma membrane targeted Epac2 FRET-based
cAMP sensors along with molecular and pharmacological approaches, they showed that
activation of muscarinic receptors leads to the receptor’s association with AKAP79 in
HEK-293 cells. AKAP79 forms a complex containing the receptor, AC2, PKC, PKA,
and PDE4. This complex results in cAMP signals that are confined in space and time.
Upon stimulation of the muscarinic receptor, PKC activates AC2 (a unique feature of this
class of AC isoforms). The cAMP produced by AC2 is short-lived since it activates
PDE4 activity via PKA, and all components are kept in close association by AKAP79
(Shen and Cooper 2013). With such tightly controlled cAMP production and
degradation, downstream effectors must be in close proximity to the AC in this case.
It is likely that AC6 is also part of signaling complexes containing PDE. PDE4
appears to play a role in preventing cAMP produced by AC6 from inducing IL-6
expression. When we treated BSMC with the PDE4-selective inhibitor rolipram,
overexpression of AC6 significantly increased IL-6 production, even at basal AC activity
(with no addition of Fsk, data not shown). The AKAP gravin orchestrates a complex
with PDE4 to restrict cAMP to the membrane region (Willoughby et al. 2006). Given
that gravin is expressed in airway smooth muscle one might hypothesize that this
complex acts to restrict the AC6 signaling compartment (Horvat et al. 2012). Further
work should seek to define all the proteins associated with the AC isoforms natively
expressed in BSMC and uncover cellular responses mediated by these different
complexes.

47

Downstream Signaling Pathways
Our data indicate that AC2-derived cAMP activates PKA and Epac (Figure 5-1),
which are both involved in regulating IL-6 expression. At low levels of cAMP, Epac is
important for transducing the signal, and at higher cAMP levels PKA plays a
predominant role. These responses may reflect different sensitivities of PKA and Epac
for cAMP or may also be reflective of how these two effectors participate in this specific
cAMP compartment. Further studies are needed to fully understand the different roles of
PKA and Epac.
Measures of bulk intracellular cAMP levels are not correlated with the amount of
IL-6 produced (Figures 4-3 and 4-4). Different receptors that stimulated both cAMP
production and IL-6 did not show a clear relationship between cAMP levels and IL-6. In
some cases, this could be explained by activation of other GPCR that stimulate Gαq and
PKC. However, Gαs-Fsk synergism using only Gαs-coupled receptors led to increased
cAMP production with no further increase in IL-6 production. It is possible that there is
a threshold after which additional cAMP has no ability to further increase IL-6
expression. Alternatively, a cAMP compartment model could also explain the lack of
correlation with large amounts of cAMP. If cAMP is not produced in the right location,
it may be unable to activate the pathways that enhance IL-6 expression. Further studies
that can detect cAMP produced in distinct subcellular compartments are needed to
understand if such pools of cAMP exist.
We sought to determine which downstream kinases are involved in induction of
IL-6 expression with the intent of determining if they are differentially activated when
AC2 or AC6 is overexpressed and activated. From the work of others it is apparent that
cAMP-mediated induction of IL-6 occurs through different pathways based on the celltype and stimulus. We used pharmacological inhibitors of three kinases that are
associated with cAMP-mediated induction of IL-6 in different cell-types. GF109203X
(PKC inhibitor), SB202190 (p38 MAPK inhibitor), and wortmanin (PI3K inhibitor) did
not inhibit IL-6 expression in response to Fsk, even when a range of concentrations was
tested (Figure 5-3). These kinases that were required for IL-6 induction in other cells are
not essential for Fsk-induced IL-6 production in BSMC. In fact, our data imply that these
pathways may tonically inhibit the induction of IL-6. There also may be significant
crosstalk among signaling pathways, so inhibition of a single intermediate does not
prevent signaling to the nucleus and induction of IL-6 expression. PKC, PI3K or p38
could be part of the signaling cascade that links surface receptors to CRE and AP-1 sites
of the IL-6 promoter, but other pathways predominate when one component is inhibited.
A schematic of the possible signal transduction pathways connecting activation of AC2 to
induction of IL-6 expression is shown in Figure 6-1.
RNA Stabilization
Throughout this work, we focused on AC2-specific enhancement of induction of
IL-6 transcription. The ability of cAMP to regulate gene expression through CRE and

48

Figure 6-1. cAMP-mediated induction of IL-6 in BSMC
Green circles represent cAMP and purple ovals represent downstream effectors.
Following stimulation by Fsk or GPCR agonists, AC2-derived cAMP activates Epac and
PKA in a signaling compartment that allows transduction of the signal to the nucleus and
induction of transcription of IL-6. PDE prevent AC6-derived cAMP from activating the
necessary intermediates for inducing IL-6 expression. cAMP stimulates IL-6 expression
through AP-1 and CRE sites. PKA-phosphorylated CREB can activate transcription
AP-1 and CRE sites, and CREB can also be phosphorylated by kinases PKC, calmodulin
kinase, and RSK2 (Wen et al. 2010). Transcription at AP-1 sites can be stimulated by
Fos/Jun through MAPK signaling pathways. There are likely many signaling pathways
driving IL-6 expression in response to cAMP.
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AP-1 promoter elements is well established (Montminy 1997). However, careful
examination of all the data from promoter activity, mRNA levels, and protein production
it becomes apparent that AC2 might also act to stabilize IL-6 mRNA and not just impact
promoter activation and transcription of IL-6. In control cells Fsk induces expression of
IL-6 mRNA. It increases promoter activity by approximately 3-fold, mRNA by 6.5-fold
at 1h, and protein by 2-fold at 24 h (Figures 5-4 and 3-6). When AC2 is overexpressed,
IL-6 mRNA is increased 77-fold over cells with endogenous AC expression following
exposure to 1-µM Fsk for 24 h (Figure 3-1). At 1 h, the effect of AC2 overexpression on
Fsk-induced IL-6 mRNA levels is less robust, with only a doubling of IL-6 mRNA
compared to control (Figure 3-7). The effect of AC2 overexpression on IL-6 abundance
is largest at the level of mRNA and has a smaller impact on promoter activation and
protein production, at least with the methods we have used. cAMP certainly does induce
transcription of IL-6 in BSMC, but the enhanced response with overexpression and
activation of AC2 may also be due to activity that stabilizes IL-6 RNA.
For some genes cAMP has been shown to increase mRNA levels via two distinct
mechanisms: increasing the rate of transcription and acting to reduce degradation of
transcripts (Hod and Hanson 1988). cAMP-mediated stabilization of lactate
dehydrogenase (LDH) A subunit mRNA involves binding of a complex of PKAphosphorylated proteins to the cAMP-stabilizing region (CSR) in the 3’-untranslated
region. The formation of the RNA stabilizing complex requires AKAP95, so AC
isoform-specific interactions are likely involved in this process too (Jungmann and
Kiryukhina 2005). Future studies should determine the stability of IL-6 transcripts in
control and AC overexpressing BSMC to see if AC2-derived cAMP specifically
stabilizes IL-6 mRNA. Addition of a transcription inhibitor such as Actinomycin D
following Fsk exposure would allow comparisons of IL-6 stability in control and AC
overexpressing cells.
Changes in Disease
BSMC from an asthmatic patient had basal levels of IL-6 mRNA that were
3-times higher than BSMC from a non-asthmatic donor (Figure 3-11). When BSMC
from the asthmatic donor were treated with 1 µM Fsk, there was no increase in IL-6
mRNA compared to those cells untreated. In non-asthmatic BSMC treated at the same
time, Fsk caused a 2.6-fold increase in IL-6 mRNA levels. There could be changes in the
cAMP signaling compartments or in downstream effector pathways that result from the
disease. BSMC from asthmatics are known to have changes in the expression of at least
one C/EBP isoform, which results in higher IL-6 expression in response to rhinovirus
infection (Oliver et al. 2006).
While we observed differences in untreated and Fsk-induced IL-6 expression by
BSMC from normal versus asthmatic donors, this study must be repeated with additional
donors to confirm the differences are due to asthma. Future work should examine
whether there are differences in relative expression and activity of different AC isoforms
among individuals and in disease. Studies to characterize the AC isoforms expressed,
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their localization, and relative activities should be repeated in diseased BSMC to
determine if there are any intrinsic differences in the cAMP signaling compartments of
asthmatic BSMC.
Phosphoproteomics
The project described here has provided as many questions as answers. We are
the first to show AC isoform-specific differences in regulation of gene expression, but
have little insight into the mechanistic details behind this phenomenon. By the time a
cAMP-mediated signal has reached the nucleus there have been many opportunities for
stimulatory and inhibitory signaling and cross talk among signaling pathways, which
make it difficult to trace an AC2-derived cAMP signal all the way to the IL-6 promoter.
Future work will look at differences downstream of individual AC isoforms that are more
proximal to cAMP production.
We are currently awaiting results from a phosphoproteomics study to identify differences
in phosphorylation patterns when different AC isoforms are overexpressed and activated
in BSMC. We used stable isotope labeling by amino acids in cell culture (SILAC) to
prepare samples for quantitative phosphoproteomic analysis. Figure 6-2 illustrates a
sample SILAC workflow. SILAC involves culturing two groups of cells in parallel in
custom media containing isotope labeled arginine and lysine. The first group is grown in
medium with unlabeled, “light” amino acids. The second group is grown in medium with
arginine and lysine containing exclusively “heavy” non-radioactive 13C and 15N. Cells
are grown in the “light” or “heavy” medium for at least 5 passages, which results in
complete incorporation of these amino acids and all proteins in the cell are isotopically
labeled (Ong and Mann 2006). For our study lacZ, AC2, or AC6 overexpressing BSMC
grown in “light” medium were treated with 1 µM Fsk for 10 min to stimulate protein
phosphorylation. The corresponding cells in “heavy” medium were vehicle-treated.
Following treatment, cells were lysed in a buffer containing protease and phosphatase
inhibitors. Total protein in sonicated lysate was determined by BCA protein assay, and
equal amounts of protein from vehicle- and Fsk- treated samples from cells
overexpressing the same AC were combined. Samples were sent to the Mass
Spectrometry and Proteomics Facility at Johns Hopkins for phosphoprotein enrichment
and mass spectrometry analysis. Analysis of these samples will identify the
phosphoproteins increased in response to Fsk treatment, and AC overexpressing cells will
be compared to control BSMC. Isotope labeling allows direct comparison between
vehicle and Fsk-treated cells, since the two samples are combined equally and prepared
and analyzed simultaneously. Proteins in lysate of Fsk-treated cells are “light” at every
lysine and arginine, so the mass to charge ratio of all trypsin-digested peptides from Fsktreated cells will be shifted to the left compared to “heavy” peptides from vehicle-treated
cells (see Figure 6-2). Relative intensities of each peptide can be compared to determine
whether cells with native AC expression and overexpressing AC2 or AC6 display
increased phosphorylation of that protein in response to 1 µM Fsk. The relative ratios of
intensity for different proteins can be compared in lacZ, AC2, and AC6 overexpressing
cells to determine if phosphorylation patterns differ with overexpression and activation of
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Figure 6-2. SILAC experimental setup
(a) Adaptation phase: “heavy” amino acids are incorporated over time with 100%
incorporation after five doublings. (b) Experimental phase: Following treatment cells
are lysed and combined 1:1 based on total protein. Samples are fractionated and
analyzed by mass spectrometry. m/z of peptides from cells grown in “heavy” medium
are shifted to the right. Relative intensity of “heavy” to “light” peak gives relative
abundance of peptide in treated compared to control samples.
Reprinted with permission.   "&$$*#    
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individual AC isoforms. Results from the SILAC phosphoproteomics study may provide
insight into signaling intermediates activated by AC2 that could induce IL-6. Results will
also be a starting point for uncovering additional AC isoform-specific cellular responses
in BSMC.
AC Isoform-Specific Regulation of Other Genes
This project primarily focused on regulation of IL-6, but the PCR array data
include other genes that are differentially regulated by individual AC isoforms that could
be of interest in regard to cAMP signaling compartments and human health (Table A-1).
With more information on the phosphorylation patterns downstream of individual AC
from our phosphoproteomics study, pathways linking specific AC isoforms to gene
regulation may become apparent. Another gene that appears to be specifically regulated
by AC2-derived cAMP is prostaglandin-endoperoxide synthase 2, also known as
cyclooxygenase 2 (COX-2). COX enzymes catalyze the first step in conversion of
aracidonic acid to prostanoids, and are important in the pathogenesis of several
inflammatory diseases (Smith et al. 2000). COX-1 is constitutively expressed, but
COX-2 is inducible, and its expression is upregulated in inflammatory diseases and many
types of cancer (Vane et al. 1998). IL-1β is one of the proinflammatory cytokines present
at higher levels in asthmatic airway, and it is one inducer of COX-2 expression in BSMC
(Pang and Knox 1997). COX-2 can also be induced by PGE2, one product of COXmediated arachadonic acid metabolism, via cAMP signaling pathways (Faour et al.
2008). The pathologic consequences of COX-2 induction can be appreciated by
observing the beneficial anti-inflammatory effects of COX-2 selective inhibitors such as
Celecoxib (Celobrex) for treatment of chronic inflammation in patients with osteoarthritis
and rheumatoid arthritis (Vane et al. 1998; FitzGerald and Patrono 2001).
Work from our lab has shown that cAMP-mediated cellular responses can be
regulated by specific AC isoforms. This project has demonstrated that individual AC
isoforms regulate expression of some cAMP-responsive genes. One gene that is of
particular interest in the pathogenesis of asthma is the pro-inflammatory cytokine IL-6,
which is induced by AC2- but not AC6-derived cAMP. βAR agonists that are used to
treat asthma may induce IL-6 via AC2 activity. As more is learned about
compartmentation of cAMP signaling and attributes of AC isoform-specific
pharmacological tools, individual AC isoforms have the potential to become therapeutic
targets. Our SILAC study could add greatly to the field as it may identify specific
patterns of kinase activity downstream of individual AC isoforms in BSMC.
Pharmaceuticals target GPCR for treatment of many diseases through activation of cAMP
signaling pathways. Receptors can be promiscuous in their coupling, allowing activation
of various unintended pathways that can worsen conditions the agonists are meant to
treat. Targeting AC directly would allow activation of cAMP signaling pathways without
the chance of Gαi or Gαq activation. Work such as ours may allow even more precise
targeting of therapeutics by identifying the individual AC isoforms and cAMP signaling
compartments that contribute to beneficial responses for treatment of disease without
activation of undesirable pathways and adverse effects.

54

LIST OF REFERENCES
Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T,
Kishimoto T (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of
a C/EBP family. Embo J 9 (6):1897-1906
Anderson GP (2006) Current issues with beta2-adrenoceptor agonists: pharmacology and
molecular and cellular mechanisms. Clinical reviews in allergy & immunology 31
(2-3):119-130. doi:10.1385/CRIAI:31:2:119
Bayewitch ML, Avidor-Reiss T, Levy R, Pfeuffer T, Nevo I, Simonds WF, Vogel Z
(1998) Inhibition of adenylyl cyclase isoforms V and VI by various Gbetagamma
subunits. The FASEB journal : official publication of the Federation of American
Societies for Experimental Biology 12 (11):1019-1025
Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ (1988) Regulation of adenylyl
cyclase-coupled beta-adrenergic receptors. Annual review of cell biology 4:405428. doi:10.1146/annurev.cb.04.110188.002201
Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, Caron MG,
Lefkowitz RJ (1985) Phosphorylation of the mammalian beta-adrenergic receptor
by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor
phosphorylation and dephosphorylation by agonist occupancy and effects on
coupling of the receptor to the stimulatory guanine nucleotide regulatory protein.
J Biol Chem 260 (11):7094-7101
Billington CK, Penn RB (2003) Signaling and regulation of G protein-coupled receptors
in airway smooth muscle. Respir Res 4 (1):2
Bogard A, Xu C, Ostrom R (2011) Human Bronchial Smooth Muscle Cells Express
Adenylyl Cyclase Isoforms 2, 4, and 6 in Distinct Membrane Microdomains. J
Pharmacol Exp Ther 337 (1):209-217. doi:10.1124/jpet.110.177923
Bogard AS, Adris P, Ostrom RS (2012) Adenylyl cyclase 2 selectively couples to E
prostanoid type 2 receptors, whereas adenylyl cyclase 3 is not receptor-regulated
in airway smooth muscle. J Pharmacol Exp Ther 342 (2):586-595.
doi:10.1124/jpet.112.193425
Bol GF, Hulster A, Pfeuffer T (1997) Adenylyl cyclase type II is stimulated by PKC via
C-terminal phosphorylation. Biochim Biophys Acta 1358 (3):307-313
Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW (2013) Isoform
Selectivity of Adenylyl Cyclase Inhibitors: Characterization of Known and Novel
Compounds. J Pharmacol Exp Ther. doi:10.1124/jpet.113.208157

55

Buxton IL, Brunton LL (1983) Compartments of cyclic AMP and protein kinase in
mammalian cardiomyocytes. J Biol Chem 258 (17):10233-10239.
Cali JJ, Zwaagstra JC, Mons N, Cooper DM, Krupinski J (1994) Type VIII adenylyl
cyclase. A Ca2+/calmodulin-stimulated enzyme expressed in discrete regions of
rat brain. The Journal of biological chemistry 269 (16):12190-12195
Chen C, Du J, Feng W, Song Y, Lu Z, Xu M, Li Z, Zhang Y (2012) beta-Adrenergic
receptors stimulate interleukin-6 production through Epac-dependent activation of
PKCdelta/p38 MAPK signalling in neonatal mouse cardiac fibroblasts. Br J
Pharmacol 166 (2):676-688. doi:10.1111/j.1476-5381.2011.01785.x
Chen J, Iyengar R (1993) Inhibition of cloned adenylyl cyclases by mutant-activated Gialpha and specific suppression of type 2 adenylyl cyclase inhibition by phorbol
ester treatment. The Journal of biological chemistry 268 (17):12253-12256
Chen Y, Harry A, Li J, Smit MJ, Bai X, Magnusson R, Pieroni JP, Weng G, Iyengar R
(1997) Adenylyl cyclase 6 is selectively regulated by protein kinase A
phosphorylation in a region involved in Galphas stimulation. Proc Natl Acad Sci
U S A 94 (25):14100-14104
Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ (1992) Longterm effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway
hyperresponsiveness in patients with mild asthma. The New England journal of
medicine 327 (17):1198-1203. doi:10.1056/NEJM199210223271703
Choi EJ, Xia Z, Storm DR (1992) Stimulation of the type III olfactory adenylyl cyclase
by calcium and calmodulin. Biochemistry 31 (28):6492-6498
Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS,
Dessauer CW, Watts VJ (2013) Development of a high-throughput screening
paradigm for the discovery of small molecule modulators of adenylyl cyclase:
Identification of an adenylyl cyclase 2 inhibitor. J Pharmacol Exp Ther.
doi:10.1124/jpet.113.207449
Conti MA, Adelstein RS (1981) The relationship between calmodulin binding and
phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3':5'
cAMP-dependent protein kinase. J Biol Chem 256 (7):3178-3181
Cooper PR, Kurten RC, Zhang J, Nicholls DJ, Dainty IA, Panettieri RA (2011)
Formoterol and salmeterol induce a similar degree of beta2-adrenoceptor
tolerance in human small airways but via different mechanisms. Br J Pharmacol
163 (3):521-532. doi:10.1111/j.1476-5381.2011.01257.x
Cumbay MG, Watts VJ (2004) Novel regulatory properties of human type 9 adenylate
cyclase. J Pharmacol Exp Ther 310 (1):108-115. doi:10.1124/jpet.104.065748

56

Daaka Y, Luttrell LM, Lefkowitz RJ (1997a) Switching of the coupling of the beta2adrenergic receptor to different G proteins by protein kinase A. Nature 390
(6655):88-91.
Daaka Y, Luttrell LM, Lefkowitz RJ (1997b) Switching of the coupling of the beta2adrenergic receptor to different G proteins by protein kinase A. Nature 390
(6655):88-91. doi:10.1038/36362
Daly JW, Jacobson KA, Ukena D (1987) Adenosine receptors: development of selective
agonists and antagonists. Progress in clinical and biological research 230:41-63
Daly JW, Padgett W, Seamon KB (1982) Activation of cyclic AMP-generating systems
in brain membranes and slices by the diterpene forskolin: augmentation of
receptor-mediated responses. J Neurochem 38 (2):532-544
Darfler FJ, Mahan LC, Koachman AM, Insel PA (1982) Stimulation of forskolin of intact
S49 lymphoma cells involves the nucleotide regulatory protein of adenylate
cyclase. J Biol Chem 257 (20):11901-11907.
de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL
(1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by
cyclic AMP. Nature 396 (6710):474-477
De S, Zelazny ET, Souhrada JF, Souhrada M (1995) IL-1 beta and IL-6 induce
hyperplasia and hypertrophy of cultured guinea pig airway smooth muscle cells. J
Appl Physiol 78 (4):1555-1563
Dendorfer U, Oettgen P, Libermann TA (1994) Multiple regulatory elements in the
interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and
lipopolysaccharide. Molecular and cellular biology 14 (7):4443-4454
Dessauer CW (2009) Adenylyl cyclase--A-kinase anchoring protein complexes: the next
dimension in cAMP signaling. Mol Pharmacol 76 (5):935-941.
doi:10.1124/mol.109.059345
Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol
Immunol 39 (9):531-536
Ding Q, Gros R, Gray ID, Taussig R, Ferguson SS, Feldman RD (2004) Raf kinase
activation of adenylyl cyclases: isoform-selective regulation. Mol Pharmacol 66
(4):921-928. doi:10.1124/mol.66.4.

57

Efendiev R, Samelson BK, Nguyen BT, Phatarpekar PV, Baameur F, Scott JD, Dessauer
CW (2010) AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and
scaffolds AC5 and -6 to alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) receptors. The Journal of biological chemistry 285
(19):14450-14458. doi:10.1074/jbc.M110.109769
Faour WH, Gomi K, Kennedy CR (2008) PGE(2) induces COX-2 expression in
podocytes via the EP(4) receptor through a PKA-independent mechanism. Cell
Signal 20 (11):2156-2164. doi:10.1016/j.cellsig.2008.08.007
Federman AD, Conklin BR, Schrader KA, Reed RR, Bourne HR (1992) Hormonal
stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature
356 (6365):159-161. doi:10.1038/356159a0
Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide
substance P activates p38 mitogen-activated protein kinase resulting in IL-6
expression independently from NF-kappa B. J Immunol 165 (10):5606-5611
Fiebich BL, Schleicher S, Spleiss O, Czygan M, Hull M (2001) Mechanisms of
prostaglandin E2-induced interleukin-6 release in astrocytes: possible
involvement of EP4-like receptors, p38 mitogen-activated protein kinase and
protein kinase C. J Neurochem 79 (5):950-958
FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N
Engl J Med 345 (6):433-442. doi:10.1056/NEJM200108093450607
Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled
receptors in the human genome form five main families. Phylogenetic analysis,
paralogon groups, and fingerprints. Mol Pharmacol 63 (6):1256-1272
Gao BN, Gilman AG (1991) Cloning and expression of a widely distributed (type IV)
adenylyl cyclase. Proc Natl Acad Sci U S A 88:10178-10182
Gao M, Ping P, Post S, Insel PA, Tang R, Hammond HK (1998) Increased expression of
adenylyl cyclase type VI proportionately increases beta-adrenergic receptorstimulated production of cAMP in neonatal rat cardiac myocytes. Proc Natl Acad
Sci U S A 95 (3):1038-1043
Gao MH, Miyanohara A, Feramisco JR, Tang T (2009) Activation of PH-domain
leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac
myocytes expressing adenylyl cyclase type 6. Biochem Biophys Res Commun
384 (2):193-198. doi:10.1016/j.bbrc.2009.04.110

58

Gao MH, Tang T, Lai NC, Miyanohara A, Guo T, Tang R, Firth AL, Yuan JX,
Hammond HK (2011) Beneficial effects of adenylyl cyclase type 6 (AC6)
expression persist using a catalytically inactive AC6 mutant. Mol Pharmacol 79
(3):381-388. doi:10.1124/mol.110.067298
Gao X, Sadana R, Dessauer CW, Patel TB (2007) Conditional stimulation of type V and
VI adenylyl cyclases by G protein betagamma subunits. The Journal of biological
chemistry 282 (1):294-302. doi:10.1074/jbc.M607522200
Georas SN, Guo J, De Fanis U, Casolaro V (2005) T-helper cell type-2 regulation in
allergic disease. Eur Respir J 26 (6):1119-1137.
doi:10.1183/09031936.05.00006005
Giembycz MA, Newton R (2006) Beyond the dogma: novel beta2-adrenoceptor
signalling in the airways. The European respiratory journal : official journal of the
European Society for Clinical Respiratory Physiology 27 (6):1286-1306.
doi:10.1183/09031936.06.00112605
Goldie RG, Spina D, Henry PJ, Lulich KM, Paterson JW (1986) In vitro responsiveness
of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists
and theophylline. British journal of clinical pharmacology 22 (6):669-676
Gonzalez GA, Montminy MR (1989) Cyclic AMP stimulates somatostatin gene
transcription by phosphorylation of CREB at serine 133. Cell 59 (4):675-680
Gros R, Ding Q, Chorazyczewski J, Pickering JG, Limbird LE, Feldman RD (2006)
Adenylyl cyclase isoform-selective regulation of vascular smooth muscle
proliferation and cytoskeletal reorganization. Circ Res 99 (8):845-852.
doi:10.1161/01.RES.0000245189.21703.c0
Hakak Y, Shrestha D, Goegel MC, Behan DP, Chalmers DT (2003) Global analysis of Gprotein-coupled receptor signaling in human tissues. Febs Lett 550 (1-3):11-17
Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132
(3):344-362. doi:10.1016/j.cell.2008.01.020
Hnasko R, Lisanti MP (2003) The biology of caveolae: lessons from caveolin knockout
mice and implications for human disease. Molecular Interventions 3 (8):445-464
Hod Y, Hanson RW (1988) Cyclic AMP stabilizes the mRNA for phosphoenolpyruvate
carboxykinase (GTP) against degradation. J Biol Chem 263 (16):7747-7752
Horvat SJ, Deshpande DA, Yan H, Panettieri RA, Codina J, Dubose TD, Jr., Xin W, Rich
TC, Penn RB (2012) A-kinase anchoring proteins regulate compartmentalized
cAMP signaling in airway smooth muscle. FASEB J 26 (9):3670-3679.
doi:10.1096/fj.11-201020

59

Inoue K, Hosoi J, Denda M (2007) Extracellular ATP has stimulatory effects on the
expression and release of IL-6 via purinergic receptors in normal human
epidermal keratinocytes. J Invest Dermatol 127 (2):362-371.
doi:10.1038/sj.jid.5700526
Insel PA, Ostrom RS (2003) Forskolin as a tool for examining adenylyl cyclase
expression, regulation, and G protein signaling. Cell Mol Neurobiol 23 (3):305314
Insel PA, Snead A, Murray F, Zhang L, Yokouchi H, Katakia T, Kwon O, Dimucci D,
Wilderman A (2012) GPCR expression in tissues and cells: are the optimal
receptors being used as drug targets? Br J Pharmacol 165 (6):1613-1616.
doi:10.1111/j.1476-5381.2011.01434.x
Iwami G, Kawabe J, Ebina T, Cannon PJ, Homcy CJ, Ishikawa Y (1995) Regulation of
adenylyl cyclase by protein kinase A. J Biol Chem 270 (21):12481-12484
Iyengar R (1993) Molecular and functional diversity of mammalian Gs-stimulated
adenylyl cyclases. FASEB J 7:768-775
Jacobowitz O, Chen J, Premont RT, Iyengar R (1993) Stimulation of specific types of
Gs-stimulated adenylyl cyclases by phorbol ester treatment. The Journal of
biological chemistry 268 (6):3829-3832
Jacobowitz O, Iyengar R (1994) Phorbol ester-induced stimulation and phosphorylation
of adenylyl cyclase 2. Proc Natl Acad Sci U S A 91 (22):10630-10634
James AL, Elliot JG, Jones RL, Carroll ML, Mauad T, Bai TR, Abramson MJ, McKay
KO, Green FH (2012) Airway smooth muscle hypertrophy and hyperplasia in
asthma. Am J Respir Crit Care Med 185 (10):1058-1064.
doi:10.1164/rccm.201110-1849OC
Johnson PR, Burgess JK, Underwood PA, Au W, Poniris MH, Tamm M, Ge Q, Roth M,
Black JL (2004) Extracellular matrix proteins modulate asthmatic airway smooth
muscle cell proliferation via an autocrine mechanism. J Allergy Clin Immunol
113 (4):690-696. doi:10.1016/j.jaci.2003.12.312
Johnston SL, Edwards MR (2009) Mechanisms of adverse effects of {beta}-agonists in
asthma. Thorax 64 (9):739-741. doi:10.1136/thx.2009.119230
Jungmann RA, Kiryukhina O (2005) Cyclic AMP and AKAP-mediated targeting of
protein kinase A regulates lactate dehydrogenase subunit A mRNA stability. J
Biol Chem 280 (26):25170-25177. doi:10.1074/jbc.M502514200

60

Kapiloff MS, Piggott LA, Sadana R, Li J, Heredia LA, Henson E, Efendiev R, Dessauer
CW (2009) An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP
levels in cardiac myocytes. J Biol Chem 284 (35):23540-23546.
doi:10.1074/jbc.M109.030072
Karin M (1996) The regulation of AP-1 activity by mitogen-activated protein kinases.
Philosophical transactions of the Royal Society of London Series B, Biological
sciences 351 (1336):127-134. doi:10.1098/rstb.1996.0008
Katsushika S, Chen L, Kawabe J, Nilakantan R, Halnon NJ, Homcy CJ, Ishikawa Y
(1992) Cloning and characterization of a sixth adenylyl cyclase isoform: types V
and VI constitute a subgroup within the mammalian adenylyl cyclase family. Proc
Natl Acad Sci U S A 89 (18):8774-8778
Kawabe J, Iwami G, Ebina T, Ohno S, Katada T, Ueda Y, Homcy CJ, Ishikawa Y (1994)
Differential activation of adenylyl cyclase by protein kinase C isoenzymes. The
Journal of biological chemistry 269 (24):16554-16558
Keely SL (1977) Activation of cAMP-dependent protein kinase without a corresponding
increase in phosphorylase activity. Research communications in chemical
pathology and pharmacology 18 (2):283-290
Keely SL (1979) Prostaglandin E1 activation of heart cAMP-dependent protein kinase:
apparent dissociation of protein kinase activation from increases in phosphorylase
activity and contractile force. Mol Pharmacol 15 (2):235-245
Knox AJ, Tattersfield AE (1995) Airway smooth muscle relaxation. Thorax 50 (8):894901
Kume H, Hall IP, Washabau RJ, Takagi K, Kotlikoff MI (1994) Beta-adrenergic agonists
regulate KCa channels in airway smooth muscle by cAMP-dependent and independent mechanisms. J Clin Invest 93 (1):371-379
Lai HL, Lin TH, Kao YY, Lin WJ, Hwang MJ, Chern Y (1999) The N terminus domain
of type VI adenylyl cyclase mediates its inhibition by protein kinase C. Mol
Pharmacol 56 (3):644-650
Lai HL, Yang TH, Messing RO, Ching YH, Lin SC, Chern Y (1997) Protein kinase C
inhibits adenylyl cyclase type VI activity during desensitization of the A2aadenosine receptor-mediated cAMP response. J Biol Chem 272 (8):4970-4977
Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM (1990) Negative and positive
regulation by transcription factor cAMP response element-binding protein is
modulated by phosphorylation. Proc Natl Acad Sci U S A 87 (11):4320-4324

61

Lavine N, Ethier N, Oak JN, Pei L, Liu F, Trieu P, Rebois RV, Bouvier M, Hebert TE,
Van Tol HH (2002) G protein-coupled receptors form stable complexes with
inwardly rectifying potassium channels and adenylyl cyclase. The Journal of
biological chemistry 277 (48):46010-46019. doi:10.1074/jbc.M205035200
Lee W, Haslinger A, Karin M, Tjian R (1987) Activation of transcription by two factors
that bind promoter and enhancer sequences of the human metallothionein gene
and SV40. Nature 325 (6102):368-372. doi:10.1038/325368a0
Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ (1990) Multiple pathways of rapid beta
2-adrenergic receptor desensitization. Delineation with specific inhibitors. The
Journal of biological chemistry 265 (6):3202-3211
Martin JG, Jo T (2008) Genetic differences in airway smooth muscle function. Proc Am
Thorac Soc 5 (1):73-79. doi:10.1513/pats.200706-069VS
Matsumoto H, Moir LM, Oliver BG, Burgess JK, Roth M, Black JL, McParland BE
(2007) Comparison of gel contraction mediated by airway smooth muscle cells
from patients with and without asthma. Thorax 62 (10):848-854.
doi:10.1136/thx.2006.070474
Metz R, Ziff E (1991) cAMP stimulates the C/EBP-related transcription factor rNFIL-6
to trans-locate to the nucleus and induce c-fos transcription. Genes Dev 5
(10):1754-1766
Mika D, Leroy J, Vandecasteele G, Fischmeister R (2012) PDEs create local domains of
cAMP signaling. J Mol Cell Cardiol 52 (2):323-329.
doi:10.1016/j.yjmcc.2011.08.016
Millet I, Vignery A (1997) The neuropeptide calcitonin gene-related peptide inhibits
TNF-alpha but poorly induces IL-6 production by fetal rat osteoblasts. Cytokine 9
(12):999-1007. doi:10.1006/cyto.1997.0245
Moffett S, Brown DA, Linder ME (2000) Lipid-dependent targeting of G proteins into
rafts. J Biol Chem 275 (3):2191-2198
Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem
66:807-822
Morjaria JB, Babu KS, Vijayanand P, Chauhan AJ, Davies DE, Holgate ST (2011)
Sputum IL-6 concentrations in severe asthma and its relationship with FEV1.
Thorax 66 (6):537. doi:10.1136/thx.2010.136523
Murthy KS (2001) cAMP inhibits IP(3)-dependent Ca(2+) release by preferential
activation of cGMP-primed PKG. American journal of physiology
Gastrointestinal and liver physiology 281 (5):G1238-1245

62

National Asthma E, Prevention P (2002) National Asthma Education and Prevention
Program. Expert Panel Report: Guidelines for the Diagnosis and Management of
Asthma Update on Selected Topics--2002. J Allergy Clin Immunol 110 (5
Suppl):S141-219
Naureckas ET, Ndukwu IM, Halayko AJ, Maxwell C, Hershenson MB, Solway J (1999)
Bronchoalveolar lavage fluid from asthmatic subjects is mitogenic for human
airway smooth muscle. Am J Respir Crit Care Med 160 (6):2062-2066.
doi:10.1164/ajrccm.160.6.9903131
Neveu WA, Allard JL, Raymond DM, Bourassa LM, Burns SM, Bunn JY, Irvin CG,
Kaminsky DA, Rincon M (2010) Elevation of IL-6 in the allergic asthmatic
airway is independent of inflammation but associates with loss of central airway
function. Respir Res 11:28. doi:10.1186/1465-9921-11-28
Oliver BG, Johnston SL, Baraket M, Burgess JK, King NJ, Roth M, Lim S, Black JL
(2006) Increased proinflammatory responses from asthmatic human airway
smooth muscle cells in response to rhinovirus infection. Respiratory Research
7:71. doi:10.1186/1465-9921-7-71
Onda T, Hashimoto Y, Nagai M, Kuramochi H, Saito S, Yamazaki H, Toya Y, Sakai I,
Homcy CJ, Nishikawa K, Ishikawa Y (2001) Type-specific regulation of adenylyl
cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase
isoforms. J Biol Chem 276 (51):47785-47793. doi:10.1074/jbc.M107233200
Ong SE, Mann M (2006) A practical recipe for stable isotope labeling by amino acids in
cell culture (SILAC). Nature protocols 1 (6):2650-2660.
doi:10.1038/nprot.2006.427
Ostrom RS, Bogard AS, Gros R, Feldman RD (2012) Choreographing the adenylyl
cyclase signalosome: sorting out the partners and the steps. Naunyn
Schmiedebergs Arch Pharmacol 385 (1):5-12. doi:10.1007/s00210-011-0696-9
Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA (2001) Receptor
number and caveolar co-localization determine receptor coupling efficiency to
adenylyl cyclase. J Biol Chem 276 (45):42063-42069.
Ostrom RS, Gregorian C, Insel PA (2000a) Cellular release of and response to ATP as
key determinants of the set-point of signal transduction pathways. J Biol Chem
275 (16):11735-11739
Ostrom RS, Insel PA (2004) The evolving role of lipid rafts and caveolae in G proteincoupled receptor signaling: Implications for molecular pharmacology. Br J
Pharmacol 143 (2):235-245

63

Ostrom RS, Liu X, Head BP, Gregorian C, Seasholtz TM, Insel PA (2002) Localization
of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth
muscle cells: expression in caveolin-rich and noncaveolin domains. Mol
Pharmacol 62 (5):983-992
Ostrom RS, Post SR, Insel PA (2000b) Stoichiometry and Compartmentation in G
Protein-coupled Receptor Signaling: Implications for Therapeutic Interventions
Involving Gs. J Pharmacol Exp Ther 294 (2):407-412
Ostrom RS, Violin JD, Coleman S, Insel PA (2000c) Selective enhancement of betaadrenergic receptor signaling by overexpression of adenylyl cyclase type 6:
colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes.
Mol Pharmacol 57 (5):1075-1079
Pang L, Knox AJ (1997) Effect of interleukin-1 beta, tumour necrosis factor-alpha and
interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human
airway smooth muscle cells. Br J Pharmacol 121 (3):579-587.
doi:10.1038/sj.bjp.0701152
Patel TB, Du Z, Pierre S, Cartin L, Scholich K (2001) Molecular biological approaches to
unravel adenylyl cyclase signaling and function. Gene 269 (1-2):13-25
Pelaia G, Cuda G, Vatrella A, Gallelli L, Caraglia M, Marra M, Abbruzzese A, Caputi M,
Maselli R, Costanzo FS, Marsico SA (2005) Mitogen-activated protein kinases
and asthma. J Cell Physiol 202 (3):642-653. doi:10.1002/jcp.20169
Pfitzer G (2001) Invited review: regulation of myosin phosphorylation in smooth muscle.
J Appl Physiol 91 (1):497-503
Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev
Mol Cell Biol 3 (9):639-650. doi:10.1038/nrm908
Pierre S, Eschenhagen T, Geisslinger G, Scholich K (2009) Capturing adenylyl cyclases
as potential drug targets. Nature reviews Drug discovery 8 (4):321-335.
doi:10.1038/nrd2827
Piggott LA, Bauman AL, Scott JD, Dessauer CW (2008) The A-kinase anchoring protein
Yotiao binds and regulates adenylyl cyclase in brain. Proc Natl Acad Sci U S A
105 (37):13835-13840. doi:10.1073/pnas.0712100105
Pike LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44 (4):655-667
Plaisance S, Vanden Berghe W, Boone E, Fiers W, Haegeman G (1997) Recombination
signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB
site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol
Cell Biol 17 (7):3733-3743

64

Prakash YS, Kannan MS, Sieck GC (1997) Regulation of intracellular calcium
oscillations in porcine tracheal smooth muscle cells. Am J Physiol 272 (3 Pt
1):C966-975
Premont RT, Matsuoka I, Mattei MG, Pouille Y, Defer N, Hanoune J (1996)
Identification and characterization of a widely expressed form of adenylyl
cyclase. J Biol Chem 271 (23):13900-13907
Raychaudhuri N, Douglas RS, Smith TJ (2010) PGE2 induces IL-6 in orbital fibroblasts
through EP2 receptors and increased gene promoter activity: implications to
thyroid-associated ophthalmopathy. PLoS One 5 (12):e15296.
doi:10.1371/journal.pone.0015296
Resh MD (2006) Palmitoylation of ligands, receptors, and intracellular signaling
molecules. Sci STKE 2006 (359):re14
Rich TC, Fagan KA, Nakata H, Schaack J, Cooper DM, Karpen JW (2000) Cyclic
nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted
cAMP diffusion. The Journal of general physiology 116 (2):147-161
Rincon M, Irvin CG (2012) Role of IL-6 in asthma and other inflammatory pulmonary
diseases. International journal of biological sciences 8 (9):1281-1290.
doi:10.7150/ijbs.4874
Rose-John S, Scheller J, Elson G, Jones SA (2006) Interleukin-6 biology is coordinated
by membrane-bound and soluble receptors: role in inflammation and cancer.
Journal of leukocyte biology 80 (2):227-236. doi:10.1189/jlb.1105674
Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, Hammond HK (2002)
Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105
(16):1989-1994
Roth M, Johnson PR, Borger P, Bihl MP, Rudiger JJ, King GG, Ge Q, Hostettler K,
Burgess JK, Black JL, Tamm M (2004) Dysfunctional interaction of C/EBPalpha
and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N
Engl J Med 351 (6):560-574. doi:10.1056/NEJMoa021660
Rubini A (2010) IL-6 increases airway resistance in the rat. Cytokine 51 (3):266-273.
doi:10.1016/j.cyto.2010.06.015
Rybin VO, Xu X, Lisanti MP, Steinberg SF (2000) Differential targeting of beta adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A
mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem
275 (52):41447-41457.

65

Salon JA, Lodowski DT, Palczewski K (2011) The significance of G protein-coupled
receptor crystallography for drug discovery. Pharmacol Rev 63 (4):901-937.
doi:10.1124/pr.110.003350
Scott JD, Dessauer CW, Tasken K (2013) Creating order from chaos: cellular regulation
by kinase anchoring. Annu Rev Pharmacol Toxicol 53:187-210.
doi:10.1146/annurev-pharmtox-011112-140204
Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, Davenport
AP, Peters JA, Spedding M, Harmar AJ, Nc I (2013) IUPHAR-DB: updated
database content and new features. Nucleic Acids Res 41 (Database
issue):D1083-1088. doi:10.1093/nar/gks960
Shaywitz AJ, Greenberg ME (1999) CREB: a stimulus-induced transcription factor
activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821861. doi:10.1146/annurev.biochem.68.1.821
Shen JX, Cooper DM (2013) AKAP79 and PKC, PKA and PDE4, participate in a Gqlinked muscarinic receptor and adenylyl cyclase 2 cAMP signalling complex.
Biochem J. doi:10.1042/BJ20130359
Shore SA (2004) Airway smooth muscle in asthma--not just more of the same. N Engl J
Med 351 (6):531-532. doi:10.1056/NEJMp048139
Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR (1986) Sequence
analysis of phospholamban. Identification of phosphorylation sites and two major
structural domains. J Biol Chem 261 (28):13333-13341
Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human
adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:381-411.
doi:10.1146/annurev.pharmtox.43.100901.135823
Smith FD, Langeberg LK, Scott JD (2006) The where's and when's of kinase anchoring.
Trends Biochem Sci 31 (6):316-323. doi:10.1016/j.tibs.2006.04.009
Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and
molecular biology. Annu Rev Biochem 69:145-182.
doi:10.1146/annurev.biochem.69.1.145
Strandberg K, Palmberg L, Larsson K (2007) Effect of formoterol and salmeterol on IL-6
and IL-8 release in airway epithelial cells. Respiratory Medicine 101 (6):11321139. doi:10.1016/j.rmed.2006.11.014
Sutkowski EM, Tang WJ, Broome CW, Robbins JD, Seamon KB (1994) Regulation of
forskolin interactions with type I, II, V and VI adenylyl cyclases by Gs alpha.
Biochemistry 33:12852-12859

66

Tanabe O, Akira S, Kamiya T, Wong GG, Hirano T, Kishimoto T (1988) Genomic
structure of the murine IL-6 gene. High degree conservation of potential
regulatory sequences between mouse and human. J Immunol 141 (11):3875-3881
Tang T, Gao MH, Hammond HK (2012) Prospects for gene transfer for clinical heart
failure. Gene Ther 19 (6):606-612. doi:10.1038/gt.2012.36
Tang WJ, Gilman AG (1991) Type-specific regulation of adenylyl cyclase by G protein
beta gamma subunits. Science 254 (5037):1500-1503
Tang WJ, Krupinski J, Gilman AG (1991) Expression and characterization of
calmodulin-activated (type I) adenylylcyclase. The Journal of biological
chemistry 266 (13):8595-8603
Taussig R, Iniguez-Lluhi JA, Gilman AG (1993a) Inhibition of adenylyl cyclase by Gi
alpha. Science 261 (5118):218-221
Taussig R, Quarmby LM, Gilman AG (1993b) Regulation of purified type I and type II
adenylylcyclases by G protein beta gamma subunits. The Journal of biological
chemistry 268 (1):9-12
Taussig R, Tang WJ, Hepler JR, Gilman AG (1994) Distinct patterns of bidirectional
regulation of mammalian adenylyl cyclases. The Journal of biological chemistry
269 (8):6093-6100
Tchivileva IE, Tan KS, Gambarian M, Nackley AG, Medvedev AV, Romanov S, Flood
PM, Maixner W, Makarov SS, Diatchenko L (2009) Signaling pathways
mediating beta3-adrenergic receptor-induced production of interleukin-6 in
adipocytes. Mol Immunol 46 (11-12):2256-2266.
doi:10.1016/j.molimm.2009.04.008
Timofeyev V, Myers RE, Kim HJ, Woltz RL, Sirish P, Heiserman JP, Li N, Singapuri A,
Tang T, Yarov-Yarovoy V, Yamoah EN, Hammond HK, Chiamvimonvat N
(2013) Adenylyl cyclase subtype-specific compartmentalization: differential
regulation of L-type Ca2+ current in ventricular myocytes. Circ Res 112
(12):1567-1576. doi:10.1161/CIRCRESAHA.112.300370
Tliba O, Panettieri RA, Jr. (2009) Noncontractile functions of airway smooth muscle
cells in asthma. Annu Rev Physiol 71:509-535.
doi:10.1146/annurev.physiol.010908.163227
Trian T, Burgess JK, Niimi K, Moir LM, Ge Q, Berger P, Liggett SB, Black JL, Oliver
BG (2011) beta2-Agonist induced cAMP is decreased in asthmatic airway smooth
muscle due to increased PDE4D. PLoS One 6 (5):e20000.
doi:10.1371/journal.pone.0020000

67

Turki J, Pak J, Green SA, Martin RJ, Liggett SB (1995) Genetic polymorphisms of the
beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that
Gly16 correlates with the nocturnal phenotype. J Clin Invest 95 (4):1635-1641.
doi:10.1172/JCI117838
Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W,
Haegeman G (1998) p38 and extracellular signal-regulated kinase mitogenactivated protein kinase pathways are required for nuclear factor-kappaB p65
transactivation mediated by tumor necrosis factor. J Biol Chem 273 (6):32853290
Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev
Pharmacol Toxicol 38:97-120. doi:10.1146/annurev.pharmtox.38.1.97
Vatner SF, Yan L, Ishikawa Y, Vatner DE, Sadoshima J (2009) Adenylyl cyclase type 5
disruption prolongs longevity and protects the heart against stress. Circ J 73
(2):195-200
Walsh DA, Perkins JP, Krebs EG (1968) An adenosine 3',5'-monophosphate-dependant
protein kinase from rabbit skeletal muscle. J Biol Chem 243 (13):3763-3765
Wang P, Zhu F, Konstantopoulos K (2010) Prostaglandin E2 induces interleukin-6
expression in human chondrocytes via cAMP/protein kinase A- and
phosphatidylinositol 3-kinase-dependent NF-kappaB activation. American journal
of physiology Cell physiology 298 (6):C1445-1456.
doi:10.1152/ajpcell.00508.2009
Watson PA, Krupinski J, Kempinski AM, Frankenfield CD (1994) Molecular cloning and
characterization of the type VII isoform of mammalian adenylyl cyclase
expressed widely in mouse tissues and in S49 mouse lymphoma cells. The Journal
of biological chemistry 269 (46):28893-28898
Wayman GA, Wei J, Wong S, Storm DR (1996) Regulation of type I adenylyl cyclase by
calmodulin kinase IV in vivo. Mol Cell Biol 16 (11):6075-6082
Wei J, Wayman G, Storm DR (1996) Phosphorylation and inhibition of type III adenylyl
cyclase by calmodulin-dependent protein kinase II in vivo. J Biol Chem 271
(39):24231-24235
Wen AY, Sakamoto KM, Miller LS (2010) The role of the transcription factor CREB in
immune function. J Immunol 185 (11):6413-6419.
doi:10.4049/jimmunol.1001829
Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM (2006) An anchored PKA and
PDE4 complex regulates subplasmalemmal cAMP dynamics. Embo J 25
(10):2051-2061. doi:10.1038/sj.emboj.7601113

68

Wooldridge AA, MacDonald JA, Erdodi F, Ma C, Borman MA, Hartshorne DJ, Haystead
TA (2004) Smooth muscle phosphatase is regulated in vivo by exclusion of
phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in
response to cyclic nucleotides. J Biol Chem 279 (33):34496-34504.
doi:10.1074/jbc.M405957200
Yeganeh B, Xia C, Movassagh H, Koziol-White C, Chang Y, Al-Alwan L, Bourke JE,
Oliver BG (2013) Emerging mediators of airway smooth muscle dysfunction in
asthma. Pulm Pharmacol Ther 26 (1):105-111. doi:10.1016/j.pupt.2012.06.011
Yoshimura M, Cooper DM (1992) Cloning and expression of a Ca(2+)-inhibitable
adenylyl cyclase from NCB-20 cells. Proc Natl Acad Sci U S A 89 (15):67166720
Zhong H, Belardinelli L, Maa T, Zeng D (2005) Synergy between A2B adenosine
receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol
Biol 32 (1):2-8. doi:10.1165/rcmb.2004-0103OC

69

APPENDIX. PCR ARRAYS
Table A-1.

Fsk-induced gene regulation in AC overexpressing BSMC compared to control BSMC
AC2

Gene

Description

ADRB1

Adrenergic, beta-1-,
receptor
Aryl hydrocarbon receptor
Adenosylmethionine
decarboxylase 1
Amphiregulin
Activating transcription
factor 3
B-cell CLL/lymphoma 2
Brain-derived neurotrophic
factor
Breast cancer 1, early onset
Calbindin 1, 28kDa
Calbindin 2
Calmodulin 1
(phosphorylase kinase,
delta)
Calreticulin
Cyclin A1

AHR
AMD1
AREG
ATF3
BCL2
BDNF
BRCA1
CALB1
CALB2
CALM1
CALR
CCNA1

AC3

AC6

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

-0.445

0.956

-0.302

0.872

1.496

0.152

1.458
1.040

1.595
1.421

-1.276
-2.709

1.189
2.176

-1.957
-2.241

1.673
2.075

3.743
2.749

2.157
1.071

1.099
-1.074

2.588
1.261

10.334
-2.488

4.347
0.733

0.534
0.864

1.124
1.048

-1.454
-1.130

0.368
1.347

0.698
-0.367

1.064
1.123

0.849
-0.445
-0.876
1.772

1.316
0.956
1.215
0.194

-0.459
-0.315
0.393
-0.774

0.808
0.880
0.708
1.043

-2.474
1.366
0.559
-1.859

0.124
0.213
0.925
1.759

0.634
1.806

1.049
1.753

-0.240
0.855

1.354
1.446

-6.404
-1.200

6.629
1.267
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Table A-1.

(Continued)
AC2

Gene

Description

CCND1
CDK5
CDKN2B

Cyclin D1
Cyclin-dependent kinase 5
Cyclin-dependent kinase
inhibitor 2B (p15, inhibits
CDK4)
Glycoprotein hormones,
alpha polypeptide
Chromogranin A
(parathyroid secretory
protein 1)
Calponin 1, basic, smooth
muscle
CAMP responsive element
binding protein 1
CAMP responsive element
modulator
Cardiotrophin 1
Cysteine-rich, angiogenic
inducer, 61
DNA-damage-inducible
transcript 3
Dual specificity
phosphatase 1
Early growth response 1

CGA
CHGA
CNN1
CREB1
CREM
CTF1
CYR61
DDIT3
DUSP1
EGR1

AC3

AC6

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

0.608
0.580
2.161

1.234
1.385
0.534

-1.668
-1.828
-1.101

1.467
1.691
1.354

-3.416
-1.970
-2.088

1.452
0.534
0.364

0.412

0.886

0.415

0.776

0.472

0.964

-0.450

0.958

-0.315

0.880

1.480

0.155

-1.138

1.204

-1.691

0.144

-1.391

0.173

0.449

1.351

-0.946

1.042

-0.813

0.927

0.864

1.433

-0.939

1.242

1.562

0.104

0.297
1.121

0.860
1.233

-0.664
0.378

0.973
0.892

-2.368
-2.096

0.784
0.346

1.856

0.485

0.468

0.875

0.785

1.794

3.385

2.744

-1.144

1.823

-0.839

1.644

3.694

2.382

-0.188

1.958

-2.223

1.977

71

Table A-1.

(Continued)
AC2

Gene

Description

EGR2
ENO2

Early growth response 2
Enolase 2 (gamma,
neuronal)
Fibroblast growth factor 6
FBJ murine osteosarcoma
viral oncogene homolog
FBJ murine osteosarcoma
viral oncogene homolog B
Glucagon
GTP binding protein
overexpressed in skeletal
muscle
Gastric inhibitory
polypeptide receptor
Hexokinase 2
Heat shock 70kDa protein
4
Heat shock 70kDa protein
5 (glucose-regulated
protein, 78kDa)
Interleukin 2
Interleukin 6 (interferon,
beta 2)
Inhibin, beta A

FGF6
FOS
FOSB
GCG
GEM
GIPR
HK2
HSPA4
HSPA5
IL2
IL6
INHBA

AC3

AC6

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

1.223
0.791

1.232
1.138

-0.315
-2.244

0.880
1.953

1.527
-1.607

0.151
0.201

-0.445
3.736

0.956
1.400

-0.315
-0.666

0.880
2.957

1.366
3.687

0.213
2.110

0.430

1.613

-0.602

0.854

-0.433

0.847

-0.445
0.406

0.956
1.102

-0.315
-1.401

0.880
1.323

1.366
-0.361

0.213
0.994

-2.301

0.570

-0.739

0.936

-0.791

0.956

0.168
-0.491

0.985
0.811

-1.086
-1.689

1.211
0.571

-0.717
-2.123

0.883
0.620

2.143

2.234

-1.599

1.515

-1.335

1.195

-0.445
77.159

0.956
50.029

-0.315
0.115

0.880
1.667

1.366
-0.469

0.213
0.747

2.066

1.850

-1.135

1.072

0.462

0.758

72

Table A-1.

(Continued)
AC2

Gene

Description

JUNB
JUND
KCNA5

Jun B proto-oncogene
Jun D proto-oncogene
Potassium voltage-gated
channel, shaker-related
subfamily, member 5
Lactate dehydrogenase A
V-maf musculoaponeurotic
fibrosarcoma oncogene
homolog (avian)
Macrophage migration
inhibitory factor
(glycosylation-inhibiting
factor)
Neural cell adhesion
molecule 1
Neurofibromin 1
Nitric oxide synthase 2,
inducible
Neuropeptide Y
Nuclear receptor subfamily
4, group A, member 2
Phosphoenolpyruvate
carboxykinase 2
(mitochondrial)

LDHA
MAF
MIF

NCAM1
NF1
NOS2
NPY
NR4A2
PCK2

AC3

AC6

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

0.721
0.171
-0.445

1.078
1.050
0.956

-1.579
-2.122
-0.315

1.499
0.706
0.880

-1.956
-0.787
1.366

0.516
1.003
0.213

-0.486
-2.022

1.901
0.453

-1.323
-1.092

1.239
1.114

0.300
-0.290

0.815
0.865

0.268

1.040

-0.595

0.912

1.283

0.139

-0.445

0.956

-0.315

0.880

1.366

0.213

-1.347
-0.445

0.156
0.956

0.187
-0.315

0.991
0.880

-1.265
1.366

0.163
0.213

0.499
6.710

0.875
4.372

-0.501
-0.419

0.798
1.573

1.364
2.391

0.078
0.833

-0.857

1.051

-2.836

0.818

-0.605

1.203
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(Continued)
AC2

Gene

AC3

AC6

Description

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

Proliferating cell nuclear
antigen
PENK
Proenkephalin
PER1
Period homolog 1
(Drosophila)
PLAT
Plasminogen activator,
tissue
PLN
Phospholamban
PMAIP1
Phorbol-12-myristate-13acetate-induced protein 1
POU1F1
POU class 1 homeobox 1
POU2AF1 POU class 2 associating
factor 1
PPP1R15A Protein phosphatase 1,
regulatory (inhibitor)
subunit 15A
PPP2CA
Protein phosphatase 2,
catalytic subunit, alpha
isozyme
PRKAR1A Protein kinase, cAMPdependent, regulatory, type
I, alpha (tissue specific
extinguisher 1)
PRL
Prolactin

0.728

1.291

-1.772

0.314

-2.075

0.511

0.621
-1.256

1.048
0.156

-1.324
-2.071

0.099
0.385

-1.358
-0.439

0.156
0.738

0.541

1.753

-1.854

0.592

-1.013

1.131

-1.680
0.617

0.379
1.374

-1.536
-1.889

0.169
0.682

0.864
1.621

1.161
0.026

-0.445
-0.398

0.956
0.939

0.384
-0.377

0.873
0.770

1.643
1.252

0.317
0.107

1.046

1.763

-1.422

1.380

-2.866

2.936

0.643

0.896

-2.441

0.794

-1.167

1.202

-0.265

1.289

-2.188

0.867

-1.532

0.220

-0.445

0.956

-0.315

0.880

1.757

0.394

PCNA
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Table A-1.

(Continued)
AC2

AC3

AC6

Gene

Description

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

PTGS2

Prostaglandinendoperoxide synthase 2
(prostaglandin G/H
synthase and
cyclooxygenase)
Retinoblastoma 1
S100 calcium binding
protein A12
S100 calcium binding
protein A6
S100 calcium binding
protein G
Secretogranin II
Serum/glucocorticoid
regulated kinase 1
Solute carrier family 18
(vesicular monoamine),
member 1
Superoxide dismutase 2,
mitochondrial
Serum response factor (cfos serum response
element-binding
transcription factor)

11.294

7.522

-0.737

1.199

2.560

1.004

1.273
-0.445

0.096
0.956

-0.440
-0.315

0.973
0.880

-0.738
1.366

0.965
0.213

-1.747

0.510

-1.924

0.186

-1.225

0.100

2.214

0.627

-0.157

0.932

2.320

0.790

-4.204
0.397

3.440
0.894

-0.944
-0.743

1.056
0.956

2.598
1.807

0.189
1.732

-0.445

0.956

-0.315

0.880

1.366

0.213

-1356.5

1369.7

-0.267

0.969

-2.159

2.664

0.458

0.864

-0.997

1.083

-0.522

1.215

RB1
S100A12
S100A6
S100G
SCG2
SGK1
SLC18A1
SOD2
SRF
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Table A-1.

(Continued)
AC2

Gene

Description

SST
SSTR2
STAT3

Somatostatin
Somatostatin receptor 2
Signal transducer and
activator of transcription 3
(acute-phase response
factor)
Tachykinin receptor 1
Transforming growth
factor, beta 3
Tyrosine hydroxylase
Thrombospondin 1
Tumor necrosis factor
Vinculin
Vasoactive intestinal
peptide

TACR1
TGFB3
TH
THBS1
TNF
VCL
VIP

AC3

AC6

Fold
Change

SEM

Fold
Change

SEM

Fold
Change

SEM

-0.826
0.363
0.434

1.466
0.989
0.900

1.072
-1.342
-1.369

1.283
0.025
0.011

9.737
2.003
-0.535

0.791
0.487
0.982

0.441
-0.301

1.027
0.831

-1.600
-1.523

0.304
0.295

0.820
0.981

1.353
1.059

-0.445
-1.681
-0.445
-0.340
1.910

0.956
0.140
0.956
1.321
0.520

-0.315
-1.649
-0.315
-0.570
-1.575

0.880
0.055
0.880
1.212
0.514

1.366
-0.792
1.366
0.836
0.169

0.213
0.956
0.213
1.330
1.120

Notes: BSMC were treated with 1 µM Fsk for 24 h. Gene expression is expressed as fold change with respect to lacZ.
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Table A-2.
Fsk-induced gene regulation in AC overexpressing HEK compared to
control HEK
Gene

Description

ADRB1
AHR
AMD1
AREG
ATF3
BCL2
BDNF
BRCA1
CALB1
CALB2
CALM1

Adrenergic, beta-1-, receptor
Aryl hydrocarbon receptor
Adenosylmethionine decarboxylase 1
Amphiregulin
Activating transcription factor 3
B-cell CLL/lymphoma 2
Brain-derived neurotrophic factor
Breast cancer 1, early onset
Calbindin 1, 28kDa
Calbindin 2
Calmodulin 1 (phosphorylase kinase,
delta)
Calreticulin
Cyclin A1
Cyclin D1
Cyclin-dependent kinase 5
Cyclin-dependent kinase inhibitor 2B
(p15, inhibits CDK4)
Glycoprotein hormones, alpha
polypeptide
Chromogranin A (parathyroid
secretory protein 1)
Calponin 1, basic, smooth muscle
CAMP responsive element binding
protein 1
CAMP responsive element modulator
Cardiotrophin 1
Cysteine-rich, angiogenic inducer, 61
DNA-damage-inducible transcript 3
Dual specificity phosphatase 1
Early growth response 1
Early growth response 2
Enolase 2 (gamma, neuronal)
Fibroblast growth factor 6
FBJ murine osteosarcoma viral
oncogene homolog

CALR
CCNA1
CCND1
CDK5
CDKN2B
CGA
CHGA
CNN1
CREB1
CREM
CTF1
CYR61
DDIT3
DUSP1
EGR1
EGR2
ENO2
FGF6
FOS
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AC2

AC6

1.879
1.2142
1.257
1.014
1.1892
1.0718
1.4743
1.0792
1.5583
1.5583
1.5583

1.3472
1.4241
-1.0425
1.4948
1.366
1.1173
1.0644
1.2058
-1.057
-1.057
1.1251

1.9453
1.3947
-148.0561
1.2226
1.4044

1.1173
1.6586
-1.4142
1.1019
1.0497

1.1728

1.7654

1.0497

-1.0943

-1.0718
1.3195

-3.0951
1.2226

1.2226
1.9453
2.1435
1.7654
1.0497
1.0644
2.4794
-1.0497
1.7171
-1.014

1.4845
-1.4743
-1.0644
1.879
1.0718
1.0943
-1.1408
-1.6358
-1.057
-1.0353

Table A-2.

(Continued)

Gene

Description

FOSB

FBJ murine osteosarcoma viral
oncogene homolog B
Glucagon
GTP binding protein overexpressed in
skeletal muscle
Gastric inhibitory polypeptide receptor
Hexokinase 2
Heat shock 70kDa protein 4
Heat shock 70kDa protein 5 (glucoseregulated protein, 78kDa)
Interleukin 2
Interleukin 6 (interferon, beta 2)
Inhibin, beta A
Jun B proto-oncogene
Jun D proto-oncogene
Potassium voltage-gated channel,
shaker-related subfamily, member 5
Lactate dehydrogenase A
V-maf musculoaponeurotic
fibrosarcoma oncogene homolog
(avian)
Macrophage migration inhibitory
factor (glycosylation-inhibiting factor)
Neural cell adhesion molecule 1
Neurofibromin 1
Nitric oxide synthase 2, inducible
Neuropeptide Y
Nuclear receptor subfamily 4, group
A, member 2
Phosphoenolpyruvate carboxykinase 2
(mitochondrial)
Proliferating cell nuclear antigen
Proenkephalin
Period homolog 1 (Drosophila)
Plasminogen activator, tissue
Phospholamban
Phorbol-12-myristate-13-acetateinduced protein 1
POU class 1 homeobox 1
POU class 2 associating factor 1

GCG
GEM
GIPR
HK2
HSPA4
HSPA5
IL2
IL6
INHBA
JUNB
JUND
KCNA5
LDHA
MAF
MIF
NCAM1
NF1
NOS2
NPY
NR4A2
PCK2
PCNA
PENK
PER1
PLAT
PLN
PMAIP1
POU1F1
POU2AF1
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AC2

AC6

1.1487

1.2924

1.5583
1.8532

-1.057
1.6472

3.9177
2
1.7777
-1.0644

1.3287
-1.0644
-1
1.6133

1.5583
1.5583
-1.0718
1.021
1.3287
1.5583

-1.057
1.6586
1.9053
-1.6358
-1.5052
-1.057

1.3104
1.5157

1.7532
2.0994

1.5583

1.8025

1.6818
1.5369
1.0425
-1.181
1.1329

2.2658
1.6472
1.3287
1.2746
1.6358

1.057

-1.0792

1.0867
1.057
1.4241
1.5052
1.1019
1.4845

1.014
-1.0497
-1.8404
1.0425
1.815
1.5476

1.5911
1.3472

1.1019
-1.3013

Table A-2.

(Continued)

Gene

Description

PPP1R15A

Protein phosphatase 1, regulatory
(inhibitor) subunit 15A
Protein phosphatase 2, catalytic
subunit, alpha isozyme
Protein kinase, cAMP-dependent,
regulatory, type I, alpha (tissue
specific extinguisher 1)
Prolactin
Prostaglandin-endoperoxide synthase
2 (prostaglandin G/H synthase and
cyclooxygenase)
Retinoblastoma 1
S100 calcium binding protein A12
S100 calcium binding protein A6
S100 calcium binding protein G
Secretogranin II
Serum/glucocorticoid regulated kinase
1
Solute carrier family 18 (vesicular
monoamine), member 1
Superoxide dismutase 2,
mitochondrial
Serum response factor (c-fos serum
response element-binding transcription
factor)
Somatostatin
Somatostatin receptor 2
Signal transducer and activator of
transcription 3 (acute-phase response
factor)
Tachykinin receptor 1
Transforming growth factor, beta 3
Tyrosine hydroxylase
Thrombospondin 1
Tumor necrosis factor
Vinculin
Vasoactive intestinal peptide

PPP2CA
PRKAR1A
PRL
PTGS2
RB1
S100A12
S100A6
S100G
SCG2
SGK1
SLC18A1
SOD2
SRF
SST
SSTR2
STAT3
TACR1
TGFB3
TH
THBS1
TNF
VCL
VIP

AC2

AC6

1.0497

-1.4948

-1

1.2746

1.3195

-1.0425

1.5583
1.1251

-1.057
1.3947

1.1975
1.5583
1.5583
3.8637
-1.2483
1.0497

1.2924
-1.057
1.0943
2.7511
1.4044
1.9053

1.5583

-1.057

1.1251

1.1728

1.2226

-1.1567

1.5583
1.6586
1.0353

-1.057
1.434
1.257

2.042
1.0943
1.5583
1.2226
1.5692
1.1173
1.8921

-1.1096
-1.366
-1.057
1.5583
4.8568
1.4641
4.4691

Notes: HEK-293 were treated with 1 µM Fsk for 24 h. Gene expression is expressed as
fold change with respect to empty pEGFP-n1 vector.
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Table A-3.

GPCR expression in BSMC

Gene

Description

LPAR1
F2R
GPR176
PDGFRB
F2RL2
SIGMAR
1
FZD1
CCRL1
NPR2
TM2D1
EDNRB
FZD6
LPHN2
GPRC5A
CD97
OPN3
NPR3
FZD7
S1PR2
OPN1SW
EDNRA
CHRM2
S1PR3
BDKRB1
FZD2
BDKRB2
XPR1
GPR157
CRCP
ELTD1

Average
CP

SD

Lysophosphatidic acid receptor 1
Coagulation factor II (thrombin) receptor
G protein-coupled receptor 176
Platelet-derived growth factor receptor, beta
polypeptide
Coagulation factor II (thrombin) receptor-like
2
Sigma non-opioid intracellular receptor 1

23.49
23.58
24.41
24.76

0.30
0.37
0.10
0.24

24.92

0.40

25.06

0.21

Frizzled family receptor 1
Chemokine (C-C motif) receptor-like 1
Natriuretic peptide receptor B/guanylate
cyclase B (atrionatriuretic peptide receptor B)
TM2 domain containing 1
Endothelin receptor type B
Frizzled family receptor 6
Latrophilin 2
G protein-coupled receptor, family C, group 5,
member A
CD97 molecule
Opsin 3
Natriuretic peptide receptor C/guanylate
cyclase C (atrionatriuretic peptide receptor C)
Frizzled family receptor 7
Sphingosine-1-phosphate receptor 2
Opsin 1 (cone pigments), short-wave-sensitive
Endothelin receptor type A
Cholinergic receptor, muscarinic 2
Sphingosine-1-phosphate receptor 3
Bradykinin receptor B1
Frizzled family receptor 2
Bradykinin receptor B2
Xenotropic and polytropic retrovirus receptor
1
G protein-coupled receptor 157
CGRP receptor component
EGF, latrophilin and seven transmembrane
domain containing 1

25.40
25.82
25.82

0.30
0.23
0.18

25.85
25.90
26.00
26.01
26.02

0.28
0.25
0.14
0.18
0.36

26.06
26.06
26.13

0.33
0.13
0.13

26.29
26.38
26.39
26.44
26.49
26.53
26.53
26.61
26.66
26.74

0.51
0.17
0.08
0.29
0.42
0.11
0.11
0.06
0.18
0.37

27.04
27.17
27.29

0.11
0.13
0.24
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Table A-3.

(Continued)

Gene

Description

OGFR
GPR153
FZD4
ADORA2
B
GPR125
SSTR1
GPR124
PDGFRL
PTGER4
LEPR
MRGPRF
MRGPR
G
S1PR1
NTSR1
FZD8
HRH1
CHRM1
PTGFR
GPRC5B
GPR161
GPR37
GPR152
F2RL1
GPR27
GPR85
GPR39
LPAR3
CNR2
SMO
CXCR7
GPR135
LPAR6
GPR173

Average
CP

SD

Opioid growth factor receptor
G protein-coupled receptor 153
Frizzled family receptor 4
Adenosine A2b receptor

27.36
27.51
27.54
27.61

0.39
0.51
0.35
0.67

G protein-coupled receptor 125
Somatostatin receptor 1
G protein-coupled receptor 124
Platelet-derived growth factor receptor-like
Prostaglandin E receptor 4 (subtype EP4)
Leptin receptor
MAS-related GPR, member F
MAS-related GPR, member G

27.62
27.62
27.68
27.71
27.71
27.74
27.78
27.85

0.47
0.10
0.02
0.66
0.31
0.22
0.45
0.91

Sphingosine-1-phosphate receptor 1
Neurotensin receptor 1 (high affinity)
Frizzled family receptor 8
Histamine receptor H1
Cholinergic receptor, muscarinic 1
Prostaglandin F receptor (FP)
G protein-coupled receptor, family C, group 5,
member B
G protein-coupled receptor 161
G protein-coupled receptor 37 (endothelin
receptor type B-like)
G protein-coupled receptor 152
Coagulation factor II (thrombin) receptor-like
1
G protein-coupled receptor 27
G protein-coupled receptor 85
G protein-coupled receptor 39
Lysophosphatidic acid receptor 3
Cannabinoid receptor 2 (macrophage)
Smoothened, frizzled family receptor
Chemokine (C-X-C motif) receptor 7
G protein-coupled receptor 135
Lysophosphatidic acid receptor 6
G protein-coupled receptor 173

27.99
28.20
28.24
28.32
28.34
28.38
28.39

0.94
0.32
0.46
0.45
0.83
0.25
0.13

28.48
28.54

0.06
0.06

28.60
28.60

0.04
0.08

28.64
28.65
28.66
28.67
28.82
28.86
29.00
29.03
29.04
29.04

0.17
0.16
0.23
0.25
0.71
0.40
0.97
0.04
0.01
0.20
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Table A-3.
Gene

(Continued)
Description

GPR1
P2RY11

G protein-coupled receptor 1
Purinergic receptor P2Y, G-protein coupled,
11
OPRD1
Opioid receptor, delta 1
CASR
Calcium-sensing receptor
SSTR4
Somatostatin receptor 4
GPR31
G protein-coupled receptor 31
ADRA1D Adrenergic, alpha-1D-, receptor
GPR162
G protein-coupled receptor 162
GABBR1 Gamma-aminobutyric acid (GABA) B
receptor, 1
F2RL3
Coagulation factor II (thrombin) receptor-like
3
GPR75
G protein-coupled receptor 75
LPHN1
Latrophilin 1
ADRB2
Adrenergic, beta-2-, receptor, surface
GPR37L1 G protein-coupled receptor 37 like 1
GPR68
G protein-coupled receptor 68
NPR1
Natriuretic peptide receptor A/guanylate
cyclase A (atrionatriuretic peptide receptor A)
HTR7
5-hydroxytryptamine (serotonin) receptor 7
(adenylate cyclase-coupled)
CHRM4
Cholinergic receptor, muscarinic 4
GPR12
G protein-coupled receptor 12
BAI2
Brain-specific angiogenesis inhibitor 2
GPR55
G protein-coupled receptor 55
CCBP2
Chemokine binding protein 2
GPR126
G protein-coupled receptor 126
GPR111
G protein-coupled receptor 111
GPR97
G protein-coupled receptor 97
LPAR5
Lysophosphatidic acid receptor 5
MRGPRD MAS-related GPR, member D
TBXA2R Thromboxane A2 receptor
CCR3
Chemokine (C-C motif) receptor 3
GPR63
G protein-coupled receptor 63
PTGIR
Prostaglandin I2 (prostacyclin) receptor (IP)
NTSR2
Neurotensin receptor 2
GPR78
G protein-coupled receptor 78
HTR3A
5-hydroxytryptamine (serotonin) receptor 3A
82

Average
CP

SD

29.10
29.13

0.08
0.03

29.29
29.36
29.38
29.56
29.62
29.64
29.65

1.06
1.24
0.59
1.34
0.64
0.16
0.03

29.71

0.78

29.78
29.85
29.90
29.96
30.09
30.15

0.25
0.18
0.56
0.52
0.35
0.77

30.17

0.91

30.22
30.23
30.26
30.37
30.38
30.40
30.53
30.56
30.61
30.65
30.66
30.68
30.70
30.73
30.76
30.83
31.12

0.46
0.11
0.26
0.07
1.15
0.41
0.71
0.47
0.18
0.22
0.12
0.62
0.16
0.17
0.08
0.34
0.91

Table A-3.

(Continued)

Gene

Description

FZD5
GPR56
GPR3
DRD4
PTGER3
RXFP3

Frizzled family receptor 5
G protein-coupled receptor 56
G protein-coupled receptor 3
Dopamine receptor D4
Prostaglandin E receptor 3 (subtype EP3)
Relaxin/insulin-like family peptide receptor
3
Chemokine (C-C motif) receptor 7
Neuromedin U receptor 1
Trace amine associated receptor 5
MAS-related GPR, member E
Leukotriene B4 receptor
G protein-coupled receptor 26
G protein-coupled receptor 65
G protein-coupled receptor 44
Arginine vasopressin receptor 1A
G protein-coupled receptor 182
Corticotropin releasing hormone receptor 1
Calcitonin receptor-like
Gonadotropin-releasing hormone receptor
Chemokine (C motif) receptor 1
Chemokine (C-X3-C motif) receptor 1
G protein-coupled receptor 160
Rhodopsin
Chemokine (C-C motif) receptor 10
Prostaglandin E receptor 1 (subtype EP1),
42kDa
Vasoactive intestinal peptide receptor 2
G protein-coupled receptor 133
Neuromedin U receptor 2
Neuropeptide S receptor 1
G protein-coupled receptor, family C, group
5, member D
Neuropeptides B/W receptor 1
Purinergic receptor P2Y, G-protein coupled,
2
Cadherin, EGF LAG seven-pass G-type
receptor 3 (flamingo homolog, Drosophila)
Adenosine A1 receptor

CCR7
NMUR1
TAAR5
MRGPRE
LTB4R
GPR26
GPR65
GPR44
AVPR1A
GPR182
CRHR1
CALCRL
GNRHR
XCR1
CX3CR1
GPR160
RHO
CCR10
PTGER1
VIPR2
GPR133
NMUR2
NPSR1
GPRC5D
NPBWR1
P2RY2
CELSR3
ADORA1
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Average
CP

SD

31.18
31.20
31.26
31.28
31.28
31.29

1.01
0.13
0.35
0.41
0.03
0.37

31.33
31.34
31.35
31.37
31.40
31.49
31.51
31.59
31.63
31.63
31.64
31.76
31.76
31.79
31.79
31.81
31.81
31.82
31.82

0.18
0.74
0.48
0.12
0.20
0.08
0.71
0.18
0.23
0.28
0.16
0.08
0.74
0.19
0.34
0.22
0.54
0.04
0.71

31.83
31.86
31.87
31.87
31.88

0.06
0.18
0.42
0.88
0.38

31.91
31.94

0.30
0.99

31.99

0.06

32.01

0.30

Table A-3.

(Continued)

Gene

Description

OPRK1
CXCR6
CELSR2
ADRA1A
GPR179
P2RY6
S1PR5
GABBR2
ADRA2A
GPR174
GPR35
GPR62
ADRA1B
GPR183
GPR21
OPRM1
CCR4
GPR142
ADORA2
A
HTR1B
GPR18
MTNR1A
PPYR1
LTB4R2
SORCS1
P2RY14
GPR45
TACR3
GPR101
GPR64
PTGDR
GPR52
PTH1R

Average
CP

SD

Opioid receptor, kappa 1
Chemokine (C-X-C motif) receptor 6
Cadherin, EGF LAG seven-pass G-type
receptor 2 (flamingo homolog, Drosophila)
Adrenergic, alpha-1A-, receptor
G protein-coupled receptor 179
Pyrimidinergic receptor P2Y, G-protein
coupled, 6
Sphingosine-1-phosphate receptor 5
Gamma-aminobutyric acid (GABA) B
receptor, 2
Adrenergic, alpha-2A-, receptor
G protein-coupled receptor 174
G protein-coupled receptor 35
G protein-coupled receptor 62
Adrenergic, alpha-1B-, receptor
G protein-coupled receptor 183
G protein-coupled receptor 21
Opioid receptor, mu 1
Chemokine (C-C motif) receptor 4
G protein-coupled receptor 142
Adenosine A2a receptor

32.02
32.06
32.07

0.28
0.37
0.11

32.09
32.12
32.20

0.51
0.11
0.37

32.26
32.29

0.42
0.95

32.32
32.32
32.33
32.34
32.35
32.39
32.41
32.42
32.45
32.45
32.47

0.57
0.17
0.68
0.40
0.54
0.11
0.11
0.43
0.51
0.25
0.01

5-hydroxytryptamine (serotonin) receptor 1B
G protein-coupled receptor 18
Melatonin receptor 1A
Pancreatic polypeptide receptor 1
Leukotriene B4 receptor 2
Sortilin-related VPS10 domain containing
receptor 1
Purinergic receptor P2Y, G-protein coupled,
14
G protein-coupled receptor 45
Tachykinin receptor 3
G protein-coupled receptor 101
G protein-coupled receptor 64
Prostaglandin D2 receptor (DP)
G protein-coupled receptor 52
Parathyroid hormone 1 receptor

32.48
32.54
32.56
32.59
32.61
32.65

0.89
0.50
0.01
0.04
0.16
0.28

32.68

0.76

32.72
32.75
32.81
32.92
32.92
32.93
32.94

1.00
0.06
0.15
0.84
1.05
0.35
0.09
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Table A-3.

(Continued)

Gene

Description

LPAR2
CHRM3
SSTR2
GHRHR
GPR77
CCKBR
HCAR1
NPBWR2
NPFFR1
TAAR2
GPR19
PTAFR
GPR149
PROKR2
GPR83
TRHR
ADRB1
GPR32
AVPR2
GPR115
GALR2
FZD9
GPR148
HCAR2
FFAR2
MC5R
LPAR4
GPR113
GPR61
GPR144
P2RY13

Lysophosphatidic acid receptor 2
Cholinergic receptor, muscarinic 3
Somatostatin receptor 2
Growth hormone releasing hormone receptor
G protein-coupled receptor 77
Cholecystokinin B receptor
Hydroxycarboxylic acid receptor 1
Neuropeptides B/W receptor 2
Neuropeptide FF receptor 1
Trace amine associated receptor 2
G protein-coupled receptor 19
Platelet-activating factor receptor
G protein-coupled receptor 149
Prokineticin receptor 2
G protein-coupled receptor 83
Thyrotropin-releasing hormone receptor
Adrenergic, beta-1-, receptor
G protein-coupled receptor 32
Arginine vasopressin receptor 2
G protein-coupled receptor 115
GALANIN RECEPTOR 2
Frizzled family receptor 9
G protein-coupled receptor 148
Hydroxycarboxylic acid receptor 2
Free fatty acid receptor 2
Melanocortin 5 receptor
Lysophosphatidic acid receptor 4
G protein-coupled receptor 113
G protein-coupled receptor 61
G protein-coupled receptor 144
Purinergic receptor P2Y, G-protein coupled,
13
Latrophilin 3
Sphingosine-1-phosphate receptor 4
5-hydroxytryptamine (serotonin) receptor 1F
G protein-coupled receptor 34
G protein-coupled receptor 82
Dopamine receptor D2

LPHN3
S1PR4
HTR1F
GPR34
GPR82
DRD2
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Average
CP

SD

32.95
33.01
33.03
33.06
33.09
33.12
33.12
33.17
33.17
33.18
33.20
33.28
33.33
33.33
33.35
33.39
33.39
33.45
33.55
33.59
33.61
33.63
33.66
33.66
33.68
33.69
33.72
33.73
33.86
33.87
33.92

0.47
0.69
1.60
0.15
0.08
1.15
0.45
0.65
0.16
1.00
1.78
0.05
1.10
1.58
0.29
0.86
0.81
0.32
0.15
0.69
0.72
0.95
0.16
0.88
0.64
1.29
1.12
0.32
0.42
0.60
0.27

33.94
33.94
33.96
34.01
34.14
34.14

0.25
0.70
1.01
0.09
0.64
0.71

Table A-3.

(Continued)

Gene

Description

O3FAR1
MCHR1
GPR84
P2RY4

Omega-3 fatty acid receptor 1
Melanin-concentrating hormone receptor 1
G protein-coupled receptor 84
Pyrimidinergic receptor P2Y, G-protein
coupled, 4
Formyl peptide receptor 1
Retinal G protein coupled receptor
Purinergic receptor P2Y, G-protein coupled, 1
Tachykinin receptor 1
Apelin receptor
Glucagon receptor
G protein-coupled receptor 6
Leucine-rich repeat containing G proteincoupled receptor 5
Trace amine associated receptor 9
(gene/pseudogene)
G protein-coupled bile acid receptor 1
Bombesin-like receptor 3
G protein-coupled receptor, family C, group 6,
member A
Glutamate receptor, metabotropic 2
G protein-coupled receptor 116
Glutamate receptor, metabotropic 7
Glutamate receptor, metabotropic 1
G protein-coupled receptor 17
Complement component 5a receptor 1
Chemokine (C-C motif) receptor 8
Retinal pigment epithelium-derived rhodopsin
homolog
Frizzled family receptor 3
G protein-coupled receptor 119
Chemokine (C-C motif) receptor 9
G protein-coupled receptor 151
G protein-coupled receptor 22
Chemokine (C-C motif) receptor 6
G protein-coupled receptor 156
5-hydroxytryptamine (serotonin) receptor 6
Duffy blood group, chemokine receptor
G protein-coupled receptor 123

FPR1
RGR
P2RY1
TACR1
APLNR
GCGR
GPR6
LGR5
TAAR9
GPBAR1
BRS3
GPRC6A
GRM2
GPR116
GRM7
GRM1
GPR17
C5AR1
CCR8
RRH
FZD3
GPR119
CCR9
GPR151
GPR22
CCR6
GPR156
HTR6
DARC
GPR123
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Average
CP

SD

34.15
34.24
34.28
34.29

0.04
0.77
0.67
0.97

34.37
34.42
34.49
34.49
34.67
34.68
34.81
34.87

0.52
1.29
0.73
1.94
1.26
0.04
0.23
0.93

34.87

0.13

34.89
34.89
35.08

2.65
0.83
1.90

35.09
35.10
35.11
35.12
35.22
35.26
35.37
35.38

1.12
0.33
0.30
0.96
0.16
0.31
1.27
1.25

35.38
35.42
35.44
35.44
35.45
35.57
35.60
35.64
35.66
35.66

1.05
0.51
1.12
0.58
4.15
1.35
1.63
0.76
1.05
0.14

Table A-3.
Gene

(Continued)
Description

NPFFR2
CXCR5
CMKLR1
TSHR
CALCR
BAI1
GPR171
GRIK3
NPY1R
GPR15
TAAR6
CXCR4
PRLHR
MC4R
GPR112
GPR139
OPN5
GPR50
NPY2R
GPR87
GLP2R
OXGR1
CXCR2
PROKR1
P2RY10

Neuropeptide FF receptor 2
Chemokine (C-X-C motif) receptor 5
CHEMOKINE-LIKE RECEPTOR 1
Thyroid stimulating hormone receptor
CALCITONIN RECEPTOR
Brain-specific angiogenesis inhibitor 1
G protein-coupled receptor 171
Glutamate receptor, ionotropic, kainate 3
Neuropeptide Y receptor Y1
G protein-coupled receptor 15
Trace amine associated receptor 6
Chemokine (C-X-C motif) receptor 4
Prolactin releasing hormone receptor
Melanocortin 4 receptor
G protein-coupled receptor 112
G protein-coupled receptor 139
Opsin 5
G protein-coupled receptor 50
Neuropeptide Y receptor Y2
G protein-coupled receptor 87
Glucagon-like peptide 2 receptor
Oxoglutarate (alpha-ketoglutarate) receptor 1
Chemokine (C-X-C motif) receptor 2
Prokineticin receptor 1
Purinergic receptor P2Y, G-protein coupled,
10
GPR128
G protein-coupled receptor 128
GALR1
Galanin receptor 1
GPR143
G protein-coupled receptor 143
HRH4
Histamine receptor H4
SSTR3
Somatostatin receptor 3
TAAR1
Trace amine associated receptor 1
MRGPRX MAS-related GPR, member X4
4
HTR2C
5-hydroxytryptamine (serotonin) receptor 2C
ADCYAP Adenylate cyclase activating polypeptide 1
1R1
(pituitary) receptor type I
HTR2A
5-hydroxytryptamine (serotonin) receptor 2A
FZD10
Frizzled family receptor 10
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Average
CP

SD

35.68
35.74
35.97
36.04
36.08
36.23
36.24
36.26
36.30
36.31
36.40
36.42
36.42
36.58
36.60
36.60
36.64
36.66
36.70
36.70
36.79
36.97
37.03
37.06
37.21

0.19
1.33
1.71
0.53
0.51
0.78
2.38
0.05
0.52
0.40
0.64
0.36
1.16
0.16
0.06
0.25
0.62
0.23
0.04
2.73
0.76
0.08
1.14
0.43
0.60

37.24
37.34
37.53
37.53
37.56
37.66
37.69

0.11
3.77
1.32
3.49
0.65
0.49
2.13

37.82
37.69

0.30
0.64

37.83
38.04

3.07
0.27

Table A-3.
Gene

(Continued)
Description

SORCS3

Sortilin-related VPS10 domain containing
receptor 3
MRGPRX MAS-related GPR, member X3
3
GRM8
Glutamate receptor, metabotropic 8
ADORA3 Adenosine A3 receptor
MRGPRX MAS-related GPR, member X2
2
CYSLTR Cysteinyl leukotriene receptor 1
1
HTR4
5-hydroxytryptamine (serotonin) receptor 4
SCTR
Secretin receptor
GPR141
G protein-coupled receptor 141
MC2R
Melanocortin 2 receptor (adrenocorticotropic
hormone)
HTR1A
5-hydroxytryptamine (serotonin) receptor 1A
AGTR2
Angiotensin II receptor, type 2
BAI3
Brain-specific angiogenesis inhibitor 3
CCRL2
Chemokine (C-C motif) receptor-like 2
CYSLTR Cysteinyl leukotriene receptor 2
2
DRD5
Dopamine receptor D5
GALR3
Galanin receptor 3
GRM5
Glutamate receptor, metabotropic 5
HCRTR1 Hypocretin (orexin) receptor 1
LHCGR
Luteinizing hormone/choriogonadotropin
receptor
OPN4
Opsin 4
P2RY12
Purinergic receptor P2Y, G-protein coupled,
12
SUCNR1 Succinate receptor 1
QRFPR
Pyroglutamylated RFamide peptide receptor
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Average
CP

SD

38.10

2.69

38.48

2.16

38.52
38.79
38.86

0.54
1.72
1.61

38.99

1.44

39.02
39.07
39.27
39.52

1.39
1.32
1.04
0.69

39.70
40.00
40.00
40.00
40.00

0.42
0.00
0.00
0.00
0.00

40.00
40.00
40.00
40.00
40.00

0.00
0.00
0.00
0.00
0.00

40.00
40.00

0.00
0.00

40.00
40.00

0.00
0.00
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